document incorporate reference document proxy statement annual meeting iii shareholder hold file securities exchange commission day close fiscal year cover reporttable content table content item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum afinancial statement note consolidated financial statement report independent register public accounting firm bsupplementary datum item change disagreement accountant account financial disclosure item control procedure management report item information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature table content item business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operate segment pharmaceutical animal health alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer october company divest consumer care segment develop manufacture market overthecounter foot care sun care product company incorporate new jersey financial information information company segment item management discussion analysis financial condition result operation item financial statement supplementary datum product service mark appear type form different surround text trademark service mark own license promote distribute merck subsidiary affiliate note trademark service mark respective owner product sale sale company pharmaceutical product total sale animal health consumer care product follow million total sale pharmaceutical januvia zetia remicade janumet gardasil isentress proquadmmr iivarivax nasonex singulair animal health consumer care revenue october company divest consumer care segment develop manufacture market overthecounter foot care sun care product revenue primarily comprise alliance revenue miscellaneous corporate revenue thirdparty manufacturing sale october company divest substantial portion thirdparty manufacturing sale table content pharmaceutical company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder certain product company franchise follow primary care women health cardiovascular zetia ezetimibe market ezetrol country outside united states vytorin ezetimibesimvastatin market inegy outside united states cholesterol modifying medicine diabete januvia sitagliptin janumet sitagliptinmetformin hcl treatment type diabete general medicine women health nuvare etonogestrelethinyl estradiol vaginal ring vaginal contraceptive product implanon etonogestrel implant singlerod subdermal contraceptive implantnexplanon etonogestrel implant single radiopaque rodshape subdermal contraceptive implant dulera inhalation aerosol mometasone furoateformoterol fumarate dihydrate combination medicine treatment asthma follistim follitropin beta injection market puregon country outside united states fertility treatment hospital specialty hepatitis pegintron peginterferon alphab victrelis boceprevir medicines treatment chronic hepatitis virus hcv hiv isentress raltegravir hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection acute care cancidas caspofungin acetate antifungal product invanz ertapenem sodium treatment certain infection noxafil posaconazole prevention invasive fungal infection bridion sugammadex injection medication reversal type neuromuscular block agent surgery primaxin imipenem cilastatin sodium antibacterial product company acquire follow product pursuant cubist pharmaceuticals inc cubist acquisition consummate january cubicin daptomycin injection antibiotic complicated skin skin structure infection bacteremia cause designate susceptible organism zerbaxa ceftolozanetazobactam combination product treatment complicate intraabdominal infection complicate urinary tract infection cause designate susceptible organism immunology remicade infliximab treatment inflammatory disease simponi golimumab oncemonthly subcutaneous treatment certain inflammatory disease company market europe russia turkey cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution company market outside united states trusopt dorzolamide hydrochloride ophthalmic solution ophthalmic product oncology emend aprepitant prevention chemotherapyinduce postoperative nausea vomit temodar temozolomide market temodal outside united states treatment certain type brain tumor keytruda pembrolizumab treatment advanced melanoma patient disease progress therapy diversify brand respiratory nasonex mometasone furoate monohydrate inhaled nasal corticosteroid treatment nasal allergy symptom singulair montelukast medicine indicate chronic treatment asthma relief symptom allergic rhinitis clarinex desloratadine nonsedate antihistamine cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide treatments hypertension arcoxia etoricoxib treatment arthritis pain company market outside united states fosamax alendronate sodium market fosamac japan treatment prevention osteoporosis propecia finasteride product treatment male pattern hair loss zocor simvastatin statin modifying cholesterol remeron mirtazapine antidepressant table content vaccine gardasil human papillomavirus quadrivalent type vaccine recombinant vaccine help prevent certain disease cause type human papillomavirus hpv proquad measle mump rubella varicella virus vaccine live pediatric combination vaccine help protect measle mump rubella varicella mmr measles mumps rubella virus vaccine live vaccine help prevent measle mump rubella varivax varicella virus vaccine live vaccine help prevent chickenpox varicella zostavax zoster vaccine live vaccine help prevent shingles herpe zoster pneumovax pneumococcal vaccine polyvalent vaccine help prevent pneumococcal disease rotateq rotavirus vaccine live oral pentavalent vaccine help protect rotavirus gastroenteritis infant child animal health animal health segment discover develop manufacture market animal health product include vaccine principal product segment include livestock product nuflor antibiotic range use cattle swine bovilisvista vaccine line infectious disease cattle banamine bovine swine antiinflammatory estrumate treatment fertility disorder cattle regumatematrix fertility management swine horse resflor combination broadspectrum antibiotic nonsteroidal antiinflammatory drug bovine respiratory disease zuprevo bovine respiratory disease zilmax revalor improve production efficiency beef cattle mpac swine pneumonia vaccine porcilis vaccine line infectious disease swine poultry product nobilisinnovax vaccine line poultry paracox coccivac coccidiosis vaccine companion animal product nobivac vaccine line flexible dog cat vaccination otomaxmometamaxposatex ear ointments acute chronic otitis caninsulinvetsulin diabete mellitus treatment dog cat panacursafeguard broadspectrum anthelmintic dewormer use animal activylscaliborexspot protect bite flea tick mosquitoe sandfly bravecto fluralaner chewable tablet kill flea tick dog week approve food drug administration fda launch approximately country aquaculture product slice parasiticide sea lice salmon aquavacnorvax vaccine bacterial viral disease fish compact vaccine salmon aquaflor antibiotic farmraised fish discussion sale company product item management discussion analysis financial condition result operation product approval september merck announce fda grant accelerated approval keytruda dose mgkg week treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor keytruda antipd program death receptor therapy approve united states august merck announce fda approve belsomra suvorexant treatment adult insomnia difficulty fall asleep andor stay asleep belsomra available united states early follow receipt marketing approval belsomra launch japan november company continue plan seek approval suvorexant country world december company announce fda approve gardasil human papillomavirus valent vaccine recombinant merck valent hpv vaccine use girl young woman year age prevention cervical vulvar vaginal anal cancer cause hpv type precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil approve use boy year age prevention anal cancer cause hpv type precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil include great number hpv type available hpv vaccine table content april merck announce fda approve grastek timothy grass pollen allergen extract ragwitek short ragweed pollen allergen extract tablet sublingual use grastek allergen extract indicate immunotherapy treatment grass polleninduce allergic rhinitis conjunctivitis confirm positive skin test vitro test pollenspecific ige antibodie timothy grass crossreactive grass pollen grastek approve use person year age ragwitek allergen extract indicate immunotherapy treatment short ragweed polleninduce allergic rhinitis conjunctivitis confirm positive skin test vitro test pollenspecific ige antibodie short ragweed pollen ragwitek approve use adult year age grastek ragwitek indicate immediate relief allergic symptom prescribe information grastek ragwitek include box warning severe allergic reaction merck announce fda approve zontivity vorapaxar reduction thrombotic cardiovascular event patient history myocardial infarction peripheral arterial disease prescribe information zontivity include box warning bleed risk january zontivity approve european commission coadministration acetylsalicylic acid appropriate clopidogrel reduce atherothrombotic event adult patient history myocardial infarction merck currently plan launch zontivity european union late early september vanihep vaniprevir oral twicedaily protease inhibitor treatment chronic hcv approve japan vanihep available japan additionally acquisition cubist company acquire zerbaxa ceftolozanetazobactam combination product approve fda december treat complicated intraabdominal infection complicate urinary tract infection cause designate susceptible organism joint venture astrazeneca june astrazeneca group plc astrazeneca exercise option purchase merck interest merck joint venture astrazeneca result astrazenecas exercise option company long record equity income azlp supply sale azlp terminate sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution thenexiste european free trade association merck sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory license subsidiary scheringplough corporation scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease schere ploughs subsidiary exercise option contract centocor license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product europe russia turkey scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis autoinjector delivery system approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi follow receipt pricing reimbursement approval company previously lose market exclusivity remicade certain small european market experience biosimilar competition decline sale market february table content company lose market exclusivity major european market company anticipate substantial decline remicade sale additionally company anticipate mandatory price reduction certain european market profit derive merck exclusive distribution product country equally divide merck competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug animal health care manufacturer company operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation patient protection affordable care act began implement insurance market reform advance state federal insurance exchange launch end decade law expect expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost marketing administrative expense table content respectively annual health care reform fee increase expense reflect final regulation annual health care reform fee issue internal revenue service irs july final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million impact health care reform predict time company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach table content sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation appears accelerate regulatory review process medicine designation adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment research development discussion regulatory approval process access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include additional law regulation enact united states europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk table content distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice hospital manage care organization company sell animal health product veterinarian distributor animal producer raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company business patent trademark license patent protection consider aggregate material importance company marketing product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage food drug administration modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant current patent law provide additional patent term patent term restoration period patent product regulatory review fda table content patent portfolio develop product introduce company normally provide market exclusivity company follow key patent protection include patent term restoration pediatric exclusivity major market product product year expiration integrilin useformulation emend follistim invanz compound composition cubicin composition zostavax use dulera formulation combination zetiavytorin asmanex formulation nasonex formulation nuvare delivery system emend injection noxafil rotateq intron recombivax method makingvectors januviajanumetjanumet compound salt isentress nexplanon device device applicator grastek use ragwitek use zontivity pende patent term restoration gardasilgardasil keytruda zerbaxa pende patent term restoration sivextro patent term restoration belsomra compound patent note certain product list subject patent litigation item financial statement supplementary datum note contingency environmental liability agreement certain generic manufacturer launch generic version integrilin june december decision district court action hospira inc hospira june patent find valid infringe later patent cubicin expire september november find invalid hospira appeal lack invalidity june patent company crossappeale invalidity late patent agreement generic manufacturer launch generic version zetia united states december district court decision uphold appeal court appeal federal circuit find propose generic product apotex generic manufacturer infringe merck nasonex formulation patent apotexs application approve fda enter market united states generic version nasonex expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states certain country market exclusivity available relevant law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset increase number incentive use generic product additionally improvement intellectual property table content law seek united states country reform patent relevant law implementation international treaty company follow key patent protection drug candidate review united states fda additional patent term provide pipeline candidate base patent term restoration pediatric exclusivity currently anticipate review year expiration corifollitropin alfa injection formulationuse pediatric hexavalent combination vaccine method makingvectors sugammadex injection company follow key patent protection drug candidate phase development currently anticipate phase drug candidate year expiration inactivated varicella zoster virus vzv vaccine use odanacatib letermovir bevenopran allergy house dust mite use anacetrapib mka actoxumabbezlotoxumab mka grazoprevirelbasvir omarigliptin bace inhibitor ertugliflozin doravirine surotomycin note patent chart compound patent patent subject future patent term restoration year month pediatric market exclusivity available addition depend circumstance surround final regulatory approval compound list patent patent application pende relevance product finally approve relevance application depend claim ultimately grant nature final regulatory approval product regulatory exclusivity tie protection clinical data complementary patent protection case provide effective long last marketing exclusivity compound patent estate united states data protection generally run year marketing approval new chemical entity extend seven year orphan drug indication year marketing approval biological product information respect company patent item risk factor item financial statement supplementary datum note contingency environmental liability worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty income patent knowhow license right amount million merck incur royalty expense amount billion patent knowhow license hold research development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity research development expense billion billion billion include restructuring cost acquisitionrelate cost year company table content prioritize research development effort focus candidate believe represent breakthrough science difference patient payer company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologics capability merck move diversify portfolio collaboration development biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality biosimilar enhance access patient worldwide company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company evaluate certain latestage clinical development platform technology asset determine outlicense sale potential company enter agreement divest sirna therapeutics inc subsidiary relate rnai technology asset outlicense investigational therapeutic antibody candidate sun pharmaceutical industries ltd sun pharma company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease osteoporosis respiratory disease women health development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug vaccine marketed united states record datum preclinical clinical experience include new drug application nda drug biologic license application bla vaccine biologic submit fda require approval company scientist discover new small molecule compound biologic molecule believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology immunogenicity toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness situation clinical program incorporate adaptive design methodology use accumulate datum decide modify aspect ongoing clinical study continue undermine validity integrity trial type adaptive clinical trial adaptive phase trial design twostage trial design consist phase proofofconcept stage phase doseoptimization finding stage datum phase trial satisfactory company commence largescale phase trial confirm compound efficacy safety type adaptive clinical trial adaptive phase trial design study include interim analysis adaptation change trial feature common phase study multiple dose group design similar phase trial adaptive phase trial design reduce timeline eliminate activity require start separate study completion phase trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market vaccine development follow general pathway drug preclinical testing focus vaccine safety ability elicit protective immune response immunogenicity premarkete vaccine clinical table content trial typically phase initial phase clinical study conduct normal subject evaluate safety tolerability immunogenicity vaccine candidate phase study doserange study finally phase trial provide necessary datum effectiveness safety successful company submit regulatory filing appropriate regulatory agency stage propose manufacturing facility undergo preapproval inspection production vaccine progress examine detail united states fda review process begin complete nda bla submit receive accept review agency day receipt fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review pursuant prescription drug user fee act fda review period target nda original bla month priority review month standard review time application deem sufficiently complete review timeline determine fda generally act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information month extension review period communicate company fda act application issue approval letter issue complete response letter crl state application approve present form describe deficiency fda identify company wish pursue application receive crl resubmit application information address question issue identify fda order support approval resubmission subject review period target vary depend underlie submission type content resubmission fda program designation fast track breakthrough therapy accelerate approval priority review facilitate expedite development review new drug address unmet medical need treatment lifethreatening condition fast track designation provide pharmaceutical manufacturer opportunitie frequent interaction fda reviewer product development ability manufacturer roll submission ndabla rolling submission allow complete portion application submit review fda ongoing basis breakthrough therapy designation provide manufacturer feature fast track designation intensive guidance implement efficient development program product commitment fda involve senior manager experience review staff review accelerate approval designation allow fda approve product base effect surrogate intermediate endpoint reasonably likely predict product clinical benefit generally require manufacturer conduct require postapproval confirmatory trial verify clinical benefit priority review designation mean fda goal action ndabla month compare month standard review addition generate antibiotic incentive act fda grant qualified infectious disease product qidp status antibacterial antifungal drug intend treat life threatening infection include cause antibiotic antifungal resistant pathogen novel emerge infectious pathogen qualify pathogen qidp designation offer certain incentive development qualify drug include priority review nda file eligibility fast track designation fiveyear extension applicable exclusivity provision food drug cosmetic act primary method company use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum marketing authorization application maa european medicine agency ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state outside united states company submit marketing application national regulatory authority example pharmaceutical medical devices agency japan health canada agencia table content nacional vigilancia brazil korea food drug administration south korea therapeutic goods administration australia country separate independent review process timeline market approval time long regulatory authority require approval major market united states issuance certificate pharmaceutical product market initiate local review process research development update company currently candidate regulatory review united states internationally keytruda antipd program death receptor therapy review ema treatment advanced melanoma september fda approve keytruda dose mgkg week treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor keytruda antipd therapy approve united states keytruda clinical development program include study cancer include bladder colorectal gastric head neck melanoma nonsmallcell lung renal triple negative breast hematological malignancy addition company announce number collaboration pharmaceutical company evaluate novel combination regimen keytruda october keytruda grant breakthrough therapy designation fda treatment patient epidermal growth factor receptor mutationnegative anaplastic lymphoma kinase rearrangementnegative non smallcell lung cancer disease progress follow platinumbase chemotherapy company anticipate submit supplemental bla fda mid keytruda bridion sugammadex injection investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent neuromuscular blockade anesthesiology induce muscle relaxation surgery september merck announce receive crl fda resubmission nda bridion address crl company conduct new hypersensitivity study october resubmitte nda fda company anticipate fda advisory committee meeting hold march review bridion approve company expect launch bridion united states later bridion approve launch country outside united states dtapipvhibhepb investigational pediatric hexavalent vaccine company develop partnership sanofi pasteur review fda ema approvedv pediatric combination vaccine united states design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis approve copromote united states partnership sanofi pasteur market spmsd joint venture europe omarigliptin investigational onceweekly dipeptidyl peptidase dpp inhibitor development treatment type diabete november merck announce company submit new drug application omarigliptin japanese pharmaceutical medical devices agency omarigliptin phase clinical development united states sivextro tedizolid phosphate oncedaily oxazolidinone antibiotic develop intravenous oral administration treatment acute bacterial skin skin structuring infection absssi cause certain grampositive organism review ema january merck announce committee medicinal product human use chmp ema adopt positive opinion recommend approval sivextro treatment absssi adult merck acquire sivextro purchase cubist affirm chmp opinion grant centralized marketing authorization unify labeling valid country member european economic area member iceland liechtenstein norway sivextro approve united states indicate treatment adult absssi cause designate susceptible grampositive organism company conduct phase clinical trial assess safety efficacy sivextro adult patient ventilate nosocomial pneumonia include ventilatorassociate bacterial pneumonia vabp ventilate hospitalacquire bacterial pneumonia ventilate habp fda designate sivextro qidp approve indication absssi table content potential indication ventilate nosocomial pneumonia include vabp ventilate habp oral dosage form mka zerbaxa combination product treatment certain bacterial infection adult review ema merck acquire zerbaxa purchase cubist december zerbaxa approve fda treatment adult complicated urinary tract infection cause designate susceptible gramnegative organism complicate intraabdominal infection cause designate susceptible gramnegative grampositive organism company conduct phase clinical trial assess safety efficacy zerbaxa adult patient ventilate nosocomial pneumonia include vabp ventilate habp fda designate zerbaxa qidp approve indication potential indication ventilate nosocomial pneumonia include vabp ventilate habp gardasil company ninevalent hpv vaccine help protect certain hpvrelate disease review ema incorporate antigen additional cancercause hpv type compare gardasil gardasil approve fda december corifollitropin alfa injection investigational fertility treatment review fda control ovarian stimulation woman participate assist reproductive technology july merck receive crl fda nda corifollitropin alfa injection merck review option respect drug candidate response crl corifollitropin alfa injection market elonva certain market outside united states addition candidate regulatory review company drug candidate phase development company anticipate file nda bla applicable fda respect certain candidate mka daily fixeddose combination chronic hcv treatment regimen consist grazoprevir investigational hcv nsa protease inhibitor elbasvir investigational hcv nsa replication complex inhibitor begin phase clinical trial june mka investigate broad clinical program include study patient multiple hcv genotype treatmentnave treatment failure fit important hcv subpopulation patient cirrhosis coinfecte hiv company expect file nda fda half mka january company receive notification fda intent rescind breakthrough therapy designation status combination treatment regimen cite availability recently approve treatment genotype patient company discuss matter fda expect impact ability file nda combination regiman time filing company start phase ccr study study combination regimen grazoprevir idx elbasvir treatment hcv infection company expect begin phase study odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis september merck announce datum pivotal phase fracture outcomes study odanacatib postmenopausal woman osteoporosis longterm odanacatib fracture trial loft odanacatib meet primary endpoint significantly reduce risk type osteoporotic fracture radiographicallyassesse vertebral clinical hip clinical nonvertebral compare placebo reduce risk secondary endpoint clinical vertebral fracture addition treatment odanacatib lead progressive increase year bone mineral density lumbar spine total hip rate adverse event overall loft generally balanced patient take odanacatib placebo adjudicate event morphealike skin lesion atypical femoral fracture occur odanacatib group placebo group adjudicate major adverse cardiovascular event generally balance overall treatment group numerically adjudicate stroke event odanacatib placebo adjudicate atrial fibrillation report odanacatib group placebo group numeric imbalance mortality observe numeric difference appear related table content particular report cause cause death merck continue collect datum blind extension study plan additional analysis datum trial include independent readjudication major adverse cardiovascular event support regulatory submission merck plan submit nda fda odanacatib merck plan submit application ema ministry health labour welfare japan investigational allergy immunotherapy tablet house dust mite allergy fda approve grastek timothy grass pollen allergen extract sublingual immunotherapy tablet ragwitek short ragweed pollen allergen extract sublingual immunotherapy tablet grastek ragwitek ongoing program north america partnership merck alkabello merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease study phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease study phase trial versus placebo patient mildtomoderate alzheimer disease epoch anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldlc anacetrapib evaluate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination monoclonal antibody treat patient single infusion surotomycin investigational oral antibiotic development treatment clostridium difficile associate diarrhea merck acquire surotomycin purchase cubist fda designate surotomycin qidp letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir receive orphan drug status united states grant fast track designation ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabete collaboration pfizer inc insulin glargine candidate treatment patient type type diabetes february company announce expand collaboration samsung bioepis develop manufacture commercialize term agreement company collaborate clinical development regulatory filing manufacture approve merck commercialize candidate inactivated vzv vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection bevenopran oral investigational therapy development potential treatment opioidinduce constipation patient chronic noncancer pain merck acquire bevenopran purchase cubist september merck sun pharma enter exclusive worldwide licensing agreement merck investigational therapeutic antibody candidate tildrakizumab treatment chronic plaque psoriasis skin ailment term agreement sun pharma acquire worldwide right tildrakizumab use human indication merck exchange upfront payment million merck continue clinical development regulatory activity fund sun pharma product approval sun pharma responsible regulatory activity include subsequent submission pharmacovigilance post approval study manufacturing commercialization approve product merck eligible receive future payment associate regulatory include product approval sale milestone tiere royalty range midsingle digit teen percentage rate sale table content merck endocyte inc endocyte company collaboration partner announce withdrawal conditional maa ema vintafolide treatment adult patient folate receptorpositive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin pld company decision base review interim datum proceed trial proceed trial terminate base datum safety monitoring board dsmb recommendation study stop vintafolide combination pld versus pld meet prespecifie criterion progressionfree survival allow continuation study dsmb identify safety concern patient enrol proceed trial june merck return worldwide right vintafolide indication endocyte chart reflect company research pipeline february candidate show phase include specific product date candidate enter phase development candidate show phase include advanced compound specific mechanism list compound mechanism currently intend commercialization give therapeutic area small molecule biologic give mknumber designation vaccine candidate give vnumber designation note candidate phase additional indication therapeutic area additional claim line extension formulation inline product show phase phase phase entry date review alzheimer disease allergy acute bacterial skin skin structure infection absssi house dust mite march sivextro asthma alzheimer disease complicated intraabdominal infection ciai complicated urinary december tract infection cuti bacterial infection atherosclerosis mka zerbaxa relebactam anacetrapib diabete mellitus cancer bladder cancer omarigliptin japan keytruda october fertility clostridium difficile infection corifollitropin alfa injection contraception medicate ius mka actoxumabbezlotoxumab hpvrelate cancer november gardasil contraception generation ring surotomycin july melanoma mkb cmv prophylaxis transplant patient keytruda ebola vaccine letermovir june neuromuscular blockade reversal diabetes mellitus bridion gastric cancer omarigliptin september pediatric hexavalent combination vaccine keytruda ertugliflozin november useu heart failure february vericiguat head neck cancer footnote hepatitis keytruda november mkmk elbasvir hepatitis develop collaboration grazoprevir mka grazoprevirelbasvir june north american rights mkmkmk herpe zoster july merck receive crl fda corifollitropin alfa grazoprevir inactivated vzv vaccine december injection merck review option respect pneumoconjugate vaccine hiv drug candidate response crl doravirine december nonsmallcell lung cancer september merck receive crl fda keytruda september resubmission nda bridion address crl opioidinduce constipation company conduct new hypersensitivity study resubmitte bevenopran october nda fda osteoporosis develop partnership sanofi pasteur approve odanacatib september copromote partnership market spmsd joint venture europe employee december company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group table content restructuring program company announce global restructure program restructuring program global initiative sharpen commercial research development focus program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacturing supply network inception restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position remain action restructure program expect substantially complete end merger restructuring program global restructuring program merger restructuring program initiate subsequent merck scheringplough merger merger intend streamline cost structure combine company action program initiate workforce reduction associate plan relate elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility inception merger restructuring program december merck eliminate approximately position comprise employee separation elimination contractor vacant position approximately position elimination remain pende program old program december nonmanufacture related restructuring action merger restructuring program substantially complete end remain action program relate ongoing manufacturing facility rationalization expect substantially complete environmental matter company believe compliance issue associate applicable environmental law regulation material adverse effect company company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million aggregate year amount consider potential recovery party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure material adverse effect company financial position result operation liquidity capital resource year merck believe climate change present risk business potential impact climate change business include increase operating cost additional regulatory requirement physical risk company facility water limitation disruption supply chain potential risk integrate company business planning include investment reduce energy water use greenhouse gas emission company believe risk material business time geographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition table content merck expand operation country locate latin america middle east africa eastern europe asia pacific business develop area stable offer important opportunity growth time financial information geographic area company business provide item financial statement supplementary datum available information company internet website address wwwmerckcom company available free charge investor portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director stand committee available company website wwwmerckcomaboutleadership information available print stockholder request company item risk factor investor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forwardlooke statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item financial statement supplementary datum note contingency environmental liability particular manufacturer generic pharmaceutical product time time file abbreviate new drug application fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case thirdparty patent prevent company marketing selling product particular geographic area additionally certain foreign government indicate compulsory license patent grant case national emergency circumstance diminish eliminate sale profit region negatively affect company result operation court decision relate company patent potential legislation relate patent regulatory initiative result erosion intellectual property protection table content important product lose patent protection profitable market sale product likely decline significantly result generic version product available case certain product loss result material noncash impairment charge company result operation adversely affect lost sale company successfully launch commercially successful replacement product chart list patent protection company major market product phase candidate set forth item business patent trademark license company product lose market exclusivity company generally experience significant rapid loss sale product company depend patent provide exclusive marketing right product period time loss patent protection company product typically lead significant rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company business cash flow result operation financial position prospect example court rule propose generic form nasonex apotex generic manufacturer infringe company patent nasonex apotex receive approval market united states generic form nasonex company experience loss nasonex sale addition september approve biosimilar remicade company experience biosimilar competition certain small european market company anticipate substantial decline remicade sale follow loss market exclusivity major european market february additionally company anticipate mandatory price reduction certain european market pursuant agreement generic manufacturer manufacturer launch united states generic version zetia december key company product generate significant company profit cash flow event adversely affect market lead product material negative impact result operation cash flow company ability generate profit operate cash flow depend largely continue profitability company key product januvia zetia remicade janumet gardasil isentress vytorin nasonex result company dependence key product event adversely affect product market product significant impact result operation cash flow event include loss patent protection increase cost associate manufacturing generic overthecounter availability company product competitive product discovery previously unknown effect result postmarket trial increase competition introduction new effective treatment discontinuation removal market product reason event material adverse effect sale certain product event result material noncash impairment charge company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year expect decline sale product loss market exclusivity mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party high rate failure inherent research development process new drug result high risk fund invest company research program generate financial return risk profile compound fact research long investment cycle bring pharmaceutical compound discovery phase market decade failure occur point process include later process significant fund invest table content description research development process item business research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal company abandon product invest substantial amount time resource risk encounter research development process include follow preclinical testing new compound yield disappointing result compete product manufacturer reach market clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug payer refuse cover reimburse new product sale new product disappointing company state certainty product development approve launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product lose market exclusivity displace compete product therapie failure short term long term material adverse effect company business result operation cash flow financial position prospect company success dependent successful development marketing new product subject substantial risk product appear promise development fail reach market fail succeed numerous reason include follow finding ineffectiveness superior safety efficacy compete product harmful effect clinical preclinical testing failure receive necessary regulatory approval include delay approval new product new indication increase uncertainty time require obtain regulatory approval benefitrisk standard apply regulatory agency determine grant approval failure certain market obtain reimbursement commensurate level innovation clinical benefit present product lack economic feasibility manufacturing cost factor preclusion commercialization proprietary right future certain pipeline program cancel company believe commercial prospect reduce company recognize material noncash impairment charge program measure fair value capitalize connection merger acquisition company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval preclude distribution sale product company successful develop new product able market product obtain require regulatory approval jurisdiction propose table content market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval development follow regulatory approval adversely affect sale company product product reach market certain development follow regulatory approval include result postmarkete phase trial study decrease demand company product include follow rereview product market new scientific information evolution scientific theory recall loss marketing approval product market change government standard public expectation safety efficacy labeling change great scrutiny advertising promotion past year clinical trial postmarkete surveillance certain market drug company competitor industry raise concern lead recall withdrawal adverse labeling market product clinical trial postmarkete surveillance certain market drug raise concern prescriber patient relate safety efficacy pharmaceutical product general negatively affect sale product addition increase scrutiny outcome clinical trial lead increase volatility market reaction matter attract litigation basis litigation groundless considerable resource need respond addition follow wake product withdrawal significant safety issue health authority fda ema japans pharmaceutical medical device agency increase focus safety assess benefitrisk balance drug health authority appear cautious making decision approvability new product indication rereviewe select product market add uncertainty regulatory process great regulatory scrutiny especially united states advertising promotion particular directtoconsumer advertising previously unknown effect discover increase negative publicity know effect company product significantly reduce demand product require company action negatively affect sale include remove product market restrict distribution apply labeling change current environment pharmaceutical company operate company risk product liability consumer protection claim civil criminal governmental action relate product research andor marketing activity company conduct tecos study involve sitagliptin result study material adverse effect sale januvia janumet trial evaluate cardiovascular outcome sitagliptin tecos eventdriven cardiovascular outcome study sitagliptin begin enrol patient tecos evaluate impact sitagliptin cardiovascular outcome add usual care compare usual care sitagliptin large highrisk type diabete population multiple country tecos expect complete quarter company expect result tecos present annual scientific session meeting american diabetes association june company sell sitagliptin januvia janumet janumet sitagliptin combine metformin immediaterelease extend release respectively treatment adult patient type diabete januviajanumetjanumet franchise company large combine worldwide sale billion table content results tecos trial negative effect cardiovascular outcome reveal safety issue relate use sitagliptin material adverse effect sale januvia janumetjanumet sales product materially adversely affect company business cash flow result operation financial position prospect materially adversely affect company face intense competition low costgeneric product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation measure encourages use generic product company policy actively protect patent right generic challenge company product arise time company patent prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially business cash flow result operation financial position prospect company face intense competition competitor product addition factor certain circumstance lead noncash impairment charge company product face intense competition competitor product competition increase new product enter market event competitor product safer effective convenient use effectively market sell company product alternatively case generic competition include generic availability competitor brand product equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business cash flow result operation financial position prospect addition product measure fair value capitalize connection merger acquisition experience difficulty market negatively impact product cash flow company recognize material noncash impairment charge respect value product company face pricing pressure respect product company face increase pricing pressure globally particularly mature market manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure company face risk litigation government pricing calculation addition large customer future ask receive high rebate drug certain highly competitive category outside united states numerous major market include japan pervasive government involvement funding health care regard fix pricing reimbursement pharmaceutical vaccine product consequently market company subject government decision make budgetary action respect product company expect pricing pressure increase future table content health care industry united states continue subject increase regulation political action company believe health care industry continue subject increase regulation political legal action future proposal reform health care system consider congress state legislature major health care reform adopt law important market reform begin continued implementation law expect expand access health care million americans end decade minimum rebate state participate medicaid program increase company brand prescription drug medicaid rebate extend medicaid manage care organization eligibility federal drug discount program extend rural referral center sole community hospital critical access hospital certain free stand cancer hospital certain additional children hospital addition law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole company require pay annual health care reform fee assess brand prescription drug manufacturer importer fee calculate base industry total sale brand prescription drug specify government program percentage manufacturer sale include determined tiere scale base manufacturers individual revenue manufacturers portion total annual fee base manufacturer proportion total includable sale prior year annual industry fee billion remain billion company predict likelihood future change health care industry general pharmaceutical industry particular impact company result operation financial condition business uncertainty global economic condition austerity measure take certain government negatively affect company operating result uncertainty global economic condition result slowdown global economy affect company business reduce price drug wholesaler retailer hospital government agency manage health care provider able willing pay company product reduce demand company product turn negatively impact company sale result material adverse effect company business cash flow result operation financial position prospect global effort health care cost containment continue exert pressure product pricing market access international market governmentmandate pricing action reduce price generic patent drug addition austerity measure include biennial price reduction japan negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance company continue monitor credit economic condition greece spain italy portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding country impact likelihood collect outstanding account receivable december company account receivable greece italy spain portugal total approximately million hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total net account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables credit economic condition europe worsen result economic currency impact affect market globally material adverse effect company result table content company significant global operation expose additional risk adverse event material negative impact company result operation extent company operation outside united states significant risk inherent conduct global business include change medical reimbursement policy program price restriction key market multiple regulatory requirement restrict company ability manufacture sell product key market trade protection measure import export licensing requirement foreign exchange fluctuation diminish protection intellectual property country possible nationalization expropriation addition change company business political position instability disruption destruction significant geographic region regardless cause include war terrorism riot civil insurrection social unrest natural manmade disaster include famine flood fire earthquake storm disease company experience difficulty delay manufacture certain product previously disclose merck past experienced difficulty manufacture certain vaccine product company future experience difficulty delay inherent manufacturing product failure company vendor supplier comply current good manufacturing practice applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture construction delay relate construction new facility expansion exist facility include intended support future demand company product iii manufacture distribution problem include change manufacture production site limit manufacturing capacity regulatory requirement change type product produce physical limitation impact continuous supply manufacturing difficulty result product shortage lead lose sale company face significant litigation relate vioxx september merck voluntarily withdraw vioxx arthritis acute pain medication market worldwide merck settle major portion product liability litigation company face material litigation arise voluntary withdrawal vioxx addition vioxx product liability lawsuit lawsuit certain state participate previouslydisclose settlement purport class action individual lawsuit bring merck current officer director merck allege merck false misleading statement vioxx violation federal security law state law suit refer vioxx security lawsuit vioxx security lawsuit transfer judicial panel multidistrict litigation district court district new jersey district judge stanley chesler inclusion nationwide multidistrict litigation consolidated purpose merck name defendant action country outside united states suit refer vioxx international lawsuit vioxx litigation discuss fully item financial statement supplementary datum note contingency environmental liability company believe meritorious defense vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx litigation vigorously defend company insurance coverage respect vioxx litigation adequate cover defense cost loss company currently able estimate additional amount require pay connection vioxx litigation proceeding expect continue year company table content predict course proceeding view inherent difficulty predict outcome litigation company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx litigation company establish material reserve potential liability relate remain vioxx litigation establish reserve relate settlement certain vioxx international lawsuit respect certain vioxx product liability lawsuit discuss item financial statement supplementary datum note contingency environmental liability unfavorable outcome vioxx litigation result payment substantial damage material adverse effect company business cash flow result operation financial position prospect company able realize expect benefit investment emerge market company take step increase presence emerge market guarantee company effort expand sale emerge market succeed country emerge market especially vulnerable period global financial instability limited resource spend health care order company successfully implement emerge market strategy attract retain qualified personnel company require increase reliance thirdparty agent develop market addition country currency fluctuate substantially currency devalue company offset devaluation company financial performance country adversely affect instance february venezuelan government devalue currency result devaluation company recognize loss exchange venezuelan government devalue currency company recognize additional loss exchange company expect impact great addition china recent governmental investigation involve multinational pharmaceutical company domestic health care company medical institute adversely affect company growth prospect market company continue believe china represent important growth opportunity event couple heighten scrutiny health care industry continue impact product pricing market access generally company anticipate report inquiry governmental authority involve multinational pharmaceutical company china continue reason sale emerge market carry significant risk failure continue expand company business emerge market material adverse effect business financial condition result company operation company expose market risk fluctuation currency exchange rate interest rate company operate multiple jurisdiction virtually sale denominate currency local jurisdiction additionally company enter enter acquisition licensing borrowing financial transaction rise currency interest rate exposure company certainty foresee mitigate adverse fluctuation fluctuation currency exchange rate interest rate negatively affect company result operation financial position cash flow occur venezuela order mitigate adverse impact market fluctuation company time time enter hedge agreement hedge agreement currency option interest rate swap limit exposure exchange rate interest rate fluctuation attempt mitigate risk costly successful company subject evolve complex tax law result additional liability affect result operation company subject evolve complex tax law jurisdiction operate significant judgment require determine company tax liability company tax return periodically table content examine tax authority company believe accrual tax contingency adequate open year base past experience interpretation tax law judgment potential action tax authority complexity tax contingency ultimate resolution tax matter result payment great amount accrue march president obamas administration repropose significant change international tax law include change tax company excess return attributable certain offshore intangible asset limit tax deduction expense relate unrepatriated foreignsource income modify foreign tax credit rule potentially significant change international law include territorial tax system tax currently accumulate unrepatriated foreign earning control foreign corporation set congressional committee company determine proposal enact law change proposal prior enact law change international tax law enact significant impact financial result company addition company affect change tax law include tax rate change change law relate remittance foreign earning deferral limitation impact tax treatment foreign earning new tax law revise tax law interpretation domestic foreign jurisdiction pharmaceutical product develop unexpected safety efficacy concern unexpected safety efficacy concern arise respect market product scientifically justified lead product recall withdrawal decline sale product liability consumer fraud andor claim include potential civil criminal governmental action change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business reliance party relationship outsource arrangement adversely affect company business company depend party include supplier alliance pharmaceutical biotechnology company party service provider key aspect business include development manufacture commercialization product support information technology system failure party meet contractual regulatory obligation company development factor materially disrupt relationship company party material adverse effect company business company increasingly dependent sophisticated information technology infrastructure company increasingly dependent sophisticated information technology infrastructure significant breakdown invasion corruption destruction interruption critical information technology system infrastructure company workforce authorize access company system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store company system nonencrypte portable medium storage device company experience business interruption intentional theft confidential information reputational damage industrial espionage attack malware cyberattack insider threat attack compromise company system infrastructure lead datum leakage internally company thirdparty provider aggregate impact company operation financial condition material date company target event nature expect continue company monitor datum information technology personnel usage company system reduce risk continue ongoing basis current potential threat assurance company effort protect datum system prevent service interruption loss critical sensitive information company table content company party provider database system result financial legal business reputational harm company social medium platform present risk challenge inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information addition negative inaccurate post comment company social networking web site damage company reputation brand image goodwill disclosure nonpublic company sensitive information company workforce external medium channel lead information loss internal company social medium policy guide employee appropriate personal professional use social medium company structured process place secure protect information identify new point entry social medium continue expand present new challenge negative event animal health industry negative impact future result operation future sale key animal health product adversely affect number risk factor include certain risk specific animal health business example outbreak disease carry animal bovine spongiform encephalopathy mad cow disease lead widespread death precautionary destruction reduce consumption demand animal adversely impact company result operation outbreak highly contagious disease near company main production site require company immediately halt production vaccine site force company incur substantial expense procure raw material vaccine risk specific animal health include epidemic pandemic government procurement pricing practice weather global agribusiness economic event animal health segment company business significant impact event future result operation significant company voluntarily suspend sale zilmax animal feed supplement united states canada concerns raise cattle fed zilmax suspension materially reduce sale zilmax company assurance sale zilmax united states canada resume biologic carry unique risk uncertainty negative impact future result operation successful development testing manufacturing commercialization biologic particularly human animal health vaccine long expensive uncertain process unique risk uncertaintie biologic include limited access supply normal diseased tissue sample cell line pathogen bacteria viral strain biological material addition government regulation multiple jurisdiction united states result restrict access transport use material company lose access sufficient source material tight restriction impose use material company able conduct research activity plan incur additional development cost development manufacturing marketing biologic subject regulation fda ema regulatory body regulation complex extensive regulation applicable pharmaceutical product example united states bla include preclinical clinical trial datum extensive datum manufacturing procedure require human vaccine candidate fda approval require release manufacture commercial lot manufacture biologic especially large quantity complex require use innovative technology handle living micro organism lot approve biologic undergo thorough testing identity strength quality purity potency manufacturing biologic table content require facility specifically design validate purpose sophisticated quality assurance quality control procedure necessary slight deviation manufacturing process include fill labeling packaging storage shipping quality control testing result lot failure product recall spoilage change manufacturing process company require provide preclinical clinical datum show comparable identity strength quality purity potency product change biologic frequently costly manufacture production ingredient derive live animal plant material biologic synthetically particular keeping demand vaccine difficult complexity produce vaccine use biologically derive ingredient lead allegation harm include infection allergic reaction closure product facility possible contamination event result substantial cost product liability insurance product limit cost prohibitive unavailable result number factor product liability insurance available cost increase significantly respect product liability company selfinsure substantially risk availability commercial insurance restrictive company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability legacy merck product sell date company continually assess efficient mean address risk guarantee insurance coverage obtained obtain sufficient fully cover product liability arise cautionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain drug candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level table content pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation include law govern intellectual property enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale significant litigation relate vioxx legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business include recently enact law majority state united states require security breach notification change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor item unresolved staff comment item property companys corporate headquarter locate kenilworth new jersey company commercial operation headquarter upper gwynedd pennsylvania company pharmaceutical business conduct divisional headquarters locate upper gwynedd cokesbury new jersey company vaccine business conduct divisional headquarters locate west point pennsylvania mercks animal health global headquarters function locate madison new jersey principal research facility locate rahway kenilworth new jersey west point pennsylvania palo alto california boston massachusetts elkhorn nebraska animal health principal research facility outside united states locate netherlands switzerland china mercks manufacturing operation headquarter whitehouse station new jersey company production facility human health product location united states puerto rico outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure billion billion billion united states amount million million billion abroad expenditure amount million million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable table content intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product item legal proceeding information call item incorporate reference item financial statement supplementary datum note contingency environmental liability item safety disclosure applicable executive officer registrant age february time merger november certain executive officer assume position merge company note kenneth frazi age december chairman president chief executive officer merck inc january president chief executive officer merck inc president merck inc responsible company large global division global human health merck manufacturing division merck research laboratory prior frazi executive vice president president global human health merck inc adele ambrose age november senior vice president chief communication officer merck inc responsible global communication organization robert davis age april executive vice president chief financial officer merck inc responsible companys global financial organization investor relation corporate strategy business development global facility company joint venture relationship prior april davis corporate vice president president medical products baxter international inc baxter corporate vice president president renal division baxter baxter corporate vice president chief financial officer willie deese age november executive vice president president merck manufacturing division merck inc responsible company global manufacturing procurement distribution logistic function richard deluca age september executive vice president president merck animal health merck inc responsible merck animal health organization prior september deluca chief financial officer becton dickinson bioscience medical technology company president wyeths fort dodge animal health division table content julie gerberde age january executive vice president strategic communication global public policy population health merck inc responsible merck global public policy corporate responsibility global communication function january president merck vaccines merck inc responsible merck portfolio vaccine plan introduction vaccine company pipeline accelerate effort broaden access merck vaccine world clark golestani age december executive vice president chief information officer merck inc responsible company global information technology organization august vice president merck research laboratorie information technology merck inc responsible global company research development division include basic research preclinical clinical regulatory mirian graddickweir age november executive vice president human resource merck inc responsible global human resource organization michael holston age june executive vice president chief ethic compliance officer merck inc responsible company global compliance function include global safety environment system assurance ethic privacy security organization prior june holston executive vice president general counsel board secretary hewlettpackard company oversaw legal compliance government affair privacy ethic operation rita karachun age march senior vice president finance global controller merck inc responsible company global controller organization include accounting control external reporting financial standard policy november assistant controller merck inc responsible global consolidation company entity act controller usbase entity bruce kuhlik age november executive vice president general counsel merck inc responsible company legal function roger perlmutter age april executive vice president president merck research laboratories merck inc responsible company global research development effort prior april perlmutter executive vice president research development amgen inc table content michael rosenblatt age december executive vice president chief medical officer merck inc company primary voice global medical community critical issue patient safety benefitrisk medication adam schechter age executive vice president president global human health merck inc responsible company global pharmaceutical vaccine business november president global human health marketintegration leader merck inc commercial responsibility united states company portfolio prescription medicine leader integration effort merckscheringplough merger division function previously announce company effective july michael holston succeed bruce kuhlik companys general counsel officer list serve pleasure board director officer elect pursuant arrangement understand officer board table content item market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information cash dividend pay common share year common stock market price high low high low january approximately shareholder record issuer purchase equity security month end december follow issuer purchase equity security millions total number average price approximate dollar value share share pay purchase period purchase share plan programs october october november november december december total share purchase period plan approve board director purchase billion merck share table content performance graph follow graph assume investment december reinvestment dividend companys common share index composite peer group major usbased pharmaceutical company abbott laboratories abbvie inc bristolmyers squibb company johnson johnson eli lilly company pfizer inc comparison fiveyear cumulative total return merck inc composite peer group index end period value cagr merck peer grp merck peer grp compound annual growth rate peer group average calculate market cap weight basis addition abbvie inc replace abbott laboratories peer group begin follow spin abbott laboratories performance graph deem incorporate reference file security act securities exchange act extent company specifically incorporate reference addition performance graph deem soliciting material file sec subject regulation provide regulation liabilities section securities exchange act extent company specifically request information treat soliciting material specifically incorporate reference filing security act exchange act table content item select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report merck inc subsidiarie million share amount result year sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder cash dividend declare cash dividend declare common share capital expenditure depreciation average common share outstanding million average common share outstanding assume dilution million yearend position work capital property plant equipment net total asset longterm debt total equity yearend statistic number stockholder record number employee amount reflect divestiture merck consumer care mcc business october include gain sale gain recognize option exercise astrazeneca gain disposition business asset loss extinguishment debt amount include net charge record connection settlement certain shareholder litigation amount include arbitration settlement charge amount include reserve relate vioxx litigation gain recognize astrazenecas exercise option acquire certain asset company table content item management discussion analysis financial condition result operation description merck business merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operate segment pharmaceutical animal health alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer october company divest consumer care segment develop manufacture market overthecounter foot care sun care product overview merck continue execute multiyear initiative sharpen commercial research development focus redesign operating model reduce cost base remain focused innovation company receive approval product united states include food drug administration fda approval keytruda treatment advanced melanoma patient disease progress therapy belsomra treatment insomnia gardasil ninevalent human papillomavirus hpv vaccine merck enhance pipeline external innovation include acquisition idenix pharmaceuticals inc idenix company engage discovery development generation treatment hepatitis virus hcv oncoethix privately hold biotechnology company specialize oncology drug development addition merck announce acquisition cubist pharmaceuticals inc cubist leader development new therapy treat potentially life threaten infection cause broad range increasingly drugresistant bacteria close january merck enter worldwide collaboration bayer bayer market develop novel therapy cardiovascular disease therapeutic indication merck prioritization effort company continue review asset determine provide well short long term value merck result company divest consumer care mcc business bayer provide capital company well resource core area focus return cash shareholder merck determine animal health business remain key growth driver commit look way augment business intensify portfolio assessment process company sell marketing right saphris antipsychotic indicate treatment schizophrenia bipolar disorder adult divest certain ophthalmic product japan markets europe asia pacific companys portfolio assessment process ongoing future divestiture occur worldwide sale billion decline compare include unfavorable effect foreign exchange decline reflect low revenue result ongoing impact product divestiture loss market exclusivity product termination company relationship astrazeneca azlp divestiture mcc addition low sale product treatment hcv contribute sale decline decline partially offset growth immunology acute care diabete vaccine product high sale merck animal health business core human pharmaceutical vaccine business merck continue support inline portfolio ongoing upcoming product launch fda grant accelerated approval keytruda company antipd program death receptor therapy treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor keytruda currently review european union treatment table content advanced melanoma merck expect submit supplemental biologic license application sbla fda keytruda treatment patient epidermal growth factor receptor mutationnegative anaplastic lymphoma kinase rearrangementnegative nonsmallcell lung cancer disease progress follow platinumbase chemotherapy midyear keytruda continue study cancer combination setting merck present datum number different tumor type research development addition fda approve belsomra treatment adult insomnia difficulty fall asleep andor stay asleep gardasil ninevalent hpv vaccine zontivity proteaseactivate receptor par antagonist reduction thrombotic cardiovascular event patient history myocardial infarction peripheral arterial disease december prior company acquisition cubist fda approve cubist zerbaxa new combination product treatment adult complicated urinary tract infection cause designate susceptible gramnegative organism complicate intraabdominal infection cause designate susceptible gramnegative grampositive organism additionally company currently candidate review fda bridion sugammadex injection medication reversal type neuromuscular block agent surgery investigational pediatric hexavalent vaccine company develop partnership sanofi pasteur design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis addition zerbaxa review result prioritize research effort merck focus therapeutic area believe impact address critical area unmet medical need cancer hepatitis cardiometabolic disease resistant microbial infection alzheimer disease merck accelerate key clinical program position company longterm growth company candidate phase clinical development core therapeutic area area significant potential mka alloral combination regimen consist grazoprevir investigational hcv nsa protease inhibitor elbasvir investigational hcv nsa replication complex inhibitor currently phase clinical trial company expect file new drug application nda fda half mka result portfolio prioritization company outlicense discontinuing select latestage clinical development asset reduce focus platform technology company outlicense tildrakizumab investigational treatment chronic plaque psoriasis divest sirna therapeutics inc subsidiary relate rnai technology asset company strong progress redesign operating model reduce cost base result discipline cost management merck remain track achieve overall saving goal end note saving enable company well target resource key priority enterprise marketing administrative expense research development cost compare reflect low sell promotional spending low cost result portfolio prioritization company announce global restructure program restructuring program global initiative sharpen commercial research development focus program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacture supply network company record total pretax cost billion related restructuring program action restructure program expect substantially complete end cumulative pretax cost estimate approximately billion company expect action restructure program result annual net cost saving approximately billion end company anticipate action restructure program combine remain action merger restructuring program discuss result annual net cost saving billion end compare fullyear expense level global restructuring program merger restructuring program initiate subsequent merck scheringplough corporation scheringplough merger merger intend table content streamline cost structure combine company workforce reduction associate plan relate elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility company record total pretax cost million billion million related restructuring program nonmanufacture related restructuring action merger restructuring program substantially complete end remain action program relate ongoing manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion yield annual saving completion program approximately billion billion cost associate company restructure action include material production cost market administrative expense research development expense restructure cost company estimate project cost associate mention restructure program approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest november mercks board director raise company quarterly dividend share share company return nearly billion shareholder dividend share repurchase earning common share assume dilution attributable common shareholder ep compare eps year reflect impact acquisition divestiturerelate cost restructure cost certain item include billion gain recognize connection divestiture mcc nongaap eps exclude item nongaap income nongaap eps competition health care environment competition market company conduct business pharmaceutical industry highly competitive highly regulate company competitor include worldwide researchbase pharmaceutical company small research company limit therapeutic focus generic drug animal health care manufacturer company operation adversely affect generic biosimilar competition company product mature technological advance competitor industry consolidation patent grant competitor competitive combination product new product competitor generic availability competitor brand product new information clinical trial market product postmarkete surveillance addition patent position increasingly challenge competitor outcome highly uncertain adverse result patent dispute preclude commercialization product negatively affect sale exist product result recognition impairment charge respect intangible asset associate certain product competitive pressure intensify pressure industry grow effect operation competitive factor patent dispute predict pharmaceutical competition involve rigorous search technological innovation ability market innovation effectively long stand emphasis research development company position compete search technological innovation additional resource require meet market challenge include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product external alliance joint venture license refine sale marketing effort address change industry condition introduction new product process competitor result price reduction product displacement product protect patent example number compound available treat particular disease typically increase time result slow sale growth reduce sale company product therapeutic category highly competitive animal health business affect factor include regulatory legislative issue scientific technological advance product innovation quality price company product effective promotional effort frequent introduction generic product competitor table content health care environment government regulation global effort health care cost containment continue exert pressure product pricing market access united states federal state government year pursue method reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity hospital serve disproportionate share low income uninsured patient backdrop united states enact major health care reform legislation patient protection affordable care act began implement insurance market reform advance state federal insurance exchange launch end decade law expect expand access health care million americans previously insurance coverage respect effect law pharmaceutical industry law increase mandate medicaid rebate expand rebate medicaid manage care utilization increase type entity eligible federal drug discount program law require pharmaceutical manufacturer pay point service discount medicare beneficiary medicare coverage gap socalle donut hole approximately million million million record merck reduction revenue respectively relate donut hole provision pharmaceutical manufacturer require pay annual nontax deductible health care reform fee total annual industry fee billion remain billion fee assess company proportion share prior year brand pharmaceutical sale certain government program medicare medicaid company record million million million cost marketing administrative expense respectively annual health care reform fee increase expense reflect final regulation annual health care reform fee issue internal revenue service irs july final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million impact health care reform predict time company face increase pricing pressure globally manage care organization government agency program negatively affect company sale profit margin united states include practice manage care group federal state exchange institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act patient protection affordable care act change health care system enact health care reform united states increase purchasing power entity negotiate behalf medicare medicaid private sector beneficiary result pricing pressure example health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate addition effort contain federal deficit pharmaceutical industry consider potential source saving legislative proposal debate enact type revenue generating cost saving proposal include additional direct price control medicare prescription drug program addition congress consider proposal allow certain condition importation medicine country remain uncertain proposal include future federal budget deficit reduction proposal directly indirectly affect company effort health care cost containment remain intense european country country continue announce execute austerity measure include implementation pricing action reduce price generic patent drug mandatory switch generic drug company take step mitigate impact country austerity measure continue negatively affect company revenue performance company anticipate austerity measure continue negatively affect revenue performance addition majority country attempt contain drug cost engage reference pricing authority examine predetermine market publish price drug brand authority use price data market set new local price brandname drug include company guideline examine reference pricing usually set local market change pursuant local regulation table content addition japan pharmaceutical industry subject governmentmandate biennial price reduction pharmaceutical product certain vaccine furthermore government order repricing class drug determine appropriate applicable rule certain market outside united states implement cost management strategy health technology assessment require additional data review administrative process increase complexity timing cost obtain product reimbursement exert downward pressure available reimbursement company focus emerge market increase government emerge market focus constrain health care cost enact price control relate measure compulsory license aim pressure price pharmaceutical constrain market access company anticipate pricing pressure market access challenge continue vary degree emerge market price market access challenge condition emerge market country affect company effort continue grow market include potential political instability significant currency fluctuation control financial crisis limit change availability funding health care development adversely impact business environment company company engage thirdparty agent assist operate emerge market country affect ability realize continued growth increase company risk exposure address cost containment pressure company engage public policy advocacy policymaker continue work demonstrate medicine provide value patient pay health care company advocate government policymaker encourage longterm approach sustainable health care financing ensure access innovative medicine disproportionately target pharmaceutical source budget saving market historically low rate health care spending company encourage government increase investment adopt market reform order improve citizen access appropriate health care include medicine operating condition challenge global pressure competition industry regulation cost containment effort predict effect factor company business company continually take measure evaluate adapt improve organization business practice well meet customer need believe position respond evolve health care environment market force pharmaceutical industry subject regulation regional country state local agency world focus standard process determine drug safety effectiveness condition sale reimbursement particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement practice increase time resource necessary develop new product bring market united states time fda commit expedite development review product bear breakthrough therapy designation appears accelerate regulatory review process medicine designation adopt directive legislation concern classification label advertise wholesale distribution integrity supply chain enhance pharmacovigilance monitor approval marketing medicinal product human use provide mandatory standard supplemented implement additional regulation member states company policy procedure consistent substance directive consequently believe material effect company business company believe continue able conduct operation include launch new drug regulatory environment table content access medicine global health care company merck primary role discover develop innovative medicine vaccine company recognize important role play helping improve access product world company effort regard wideranging include set principle company strive embed operation business strategy guide company worldwide approach expand access health care addition company farreache philanthropic program merck patient assistance program provide medicine adult vaccine free people united states prescription drug health insurance coverage company assistance afford merck medicine vaccine merck launch merck mother longterm effort global health partner end preventable death complication pregnancy childbirth merck provide fund merck foundation independent organization partner variety organization dedicate improve global health privacy datum protection company subject significant number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase attention privacy datum protection issue develop emerge market potential affect directly company business include additional law regulation enact united states europe asia latin america increase enforcement litigation activity united states develop market increase regulatory cooperation privacy authority globally company adopt comprehensive global privacy program manage evolve risk operate result sale worldwide sale total billion decline compare billion foreign exchange unfavorably affect global sale performance decline reflect low revenue result ongoing impact loss market exclusivity product include temodar treatment certain type brain tumor singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis cozaar hyzaar treatments hypertension addition sale decline attributable product divestiture occurred discuss termination company relationship azlp divestiture mcc october revenue decline drive low sale victreli pegintron medicine treatment chronic hcv nasonex inhale nasal corticosteroid treatment nasal allergy symptom vytorin cholesterol modifying product decline partially offset growth remicade simponi treatment inflammatory disease diabetes franchise januviajanumet dulera inhalation aerosol combination medicine treatment asthma implanonnexplanon singlerod subdermal contraceptive implant high sale acute care animal health product addition company recognize revenue million connection sale marketing right saphris sales united states billion decline compare billion sale decrease drive primarily termination company relationship azlp divestiture mcc ongoing impact product divestiture addition decline reflect low sale temodar victrelis vytorin nasonex partially offset high sale dulera inhalation aerosol januviajanumet franchise implanonnexplanon revenue recognize connection sale marketing right saphris international sale billion decline compare billion foreign exchange unfavorably affect international sale performance sale decrease reflect divestiture mcc decline drive low sale pharmaceutical segment reflect decline japan europe canada sales japan decline billion unfavorable effect foreign exchange sale decline largely drive biennial price reduction repricing occur product divestiture ongoing impact loss market exclusivity product include cozaar hyzaar low sale gardasil vaccine help prevent certain disease cause type hpv reflect japanese government decision suspend proactive recommendation hpv vaccine partially offset high sale pneumovax vaccine help prevent pneumococcal disease sale europe table content canada decline billion include favorable effect foreign exchange reflect low sale singulair nasonex victrelis product divestiture ongoing generic erosion fiscal austerity measure region partially offset growth simponi remicade janumet januvia sale emerge market billion essentially flat compare include unfavorable effect foreign exchange reflect high sale vaccine acute care diabetes product offset low sale hcv product product divestiture total international sale represent total sale respectively global effort health care cost containment continue exert pressure product pricing market access worldwide united states health care reform contribute increase number patient medicaid program sale pharmaceutical product subject substantial rebate international market governmentmandate pricing action reduce price generic patent drug addition austerity measure negatively affect company revenue performance company anticipate pricing action austerity measure continue negatively affect revenue performance october company sell active pharmaceutical ingredient api manufacturing business netherland effective december certain relate product diversified brand november merck sell right certain ophthalmic product january sell marketing right saphris addition company sell right zioptan april divest certain ophthalmic product international market close july october company sell mcc business bayer include prescription right claritin afrin sale decline attributable divestiture approximately billion approximately million related pharmaceutical segment million relate consumer care segment million relate divested api manufacturing business nonsegment revenue discuss note consolidated financial statement company relationship azlp terminate june effective july company long record supply sale azlp result sale decline approximately million alliance segment worldwide sale total billion decline compare billion sale decline drive primarily low sale singulair patent provide market exclusivity market exclusivity number major european market singulair expire august february respectively company experience significant rapid decline singulair sale market foreign exchange unfavorably affect global sale performance revenue decline drive low sale maxalt product acute treatment migraine cozaar hyzaar temodar clarinex nonsedate antihistamine pegintron propecia product male pattern hair loss fosamax treatment osteoporosis vytorin decline partially offset growth gardasil remicade simponi janumet isentress treatment hiv infection dulera inhalation aerosol zostavax vaccine help prevent shingles herpe zoster table content sale company product follow million primary care women health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis pegintron victrelis hiv isentress acute care cancidas invanz noxafil bridion primaxin immunology remicade simponi cosopttrusopt oncology emend temodar keytruda diversify brand respiratory nasonex singulair clarinex cozaarhyzaar arcoxia fosamax propecia zocor remeron vaccines gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separatelyrepresent nonreportable segment animal health alliance consumer care divestiture october alliance segment include revenue company relationship azlp termination june revenues primarily comprise miscellaneous corporate revenue include revenue hedging activity sale relate divested product business supply sale include segment result revenue include million receive merck connection sale marketing right saphris revenue reflect million revenue outlicense pipeline compound revenue include thirdparty manufacture sale substantial portion divest october table content pharmaceutical segment primary care women health cardiovascular combine global sale zetia market country outside united states ezetrol vytorin market outside united states inegy medicine lower ldl cholesterol billion decline compare foreign exchange unfavorably affect global sale performance sale decline drive primarily low volume vytorin united states zetia canada lose market exclusivity combine worldwide sale zetia vytorin billion essentially flat compare include unfavorable impact foreign exchange reflect high sale zetia united states pricing partially offset low volume vytorin united states november merck announce investigational improveit study meet primary secondary composite efficacy endpoint improveit patient take vytorin combine simvastatin zetia ezetimibe experience significantly few major cardiovascular event measure composite cardiovascular death nonfatal myocardial infarction nonfatal stroke rehospitalization unstable angina coronary revascularization occur day randomization patient treat simvastatin result patient study highrisk patient present acute coronary syndrome present american heart association scientific session merck plan submit datum improveit fda mid support new indication reduction major cardiovascular event vytorin zetia vytorin zetia currently indicate use healthy diet reduce elevated ldl cholesterol patient hyperlipidemia current prescribe information product states effect ezetimibe cardiovascular morbidity mortality incremental statin therapy determine agreement generic manufacturer launch generic version zetia united states december patent exclusivity period zetia vytorin expire april company market exclusivity zetia major european market october company expect apply pediatric extension term extend date april company market exclusivity vytorin market april business reason company plan time reintroduce liptruzet market company supply liptruzet united states january voluntary recall product packaging defect active ingredient liptruzet remain available zetia merck atorvastatin generic multiple manufacturer merck announce fda approve zontivity reduction thrombotic cardiovascular event patient history myocardial infarction peripheral arterial disease prescribe information zontivity include box warning bleed risk january zontivity approve european commission coadministration acetylsalicylic acid appropriate clopidogrel reduce atherothrombotic event adult patient history myocardial infarction merck currently plan launch zontivity late early diabete worldwide combine sale januvia janumet medicine help lower blood sugar level adult type diabete billion increase compare include unfavorable effect foreign exchange growth drive primarily high sale januvia janumet united states volume growth europe partially offset low sale januvia japan low pricing april dipeptidyl peptidase dpp inhibitor include januvia subject reprice japan combine global sale januvia janumet billion increase compare include unfavorable effect foreign exchange sale growth reflect high volume outside united states trial evaluate cardiovascular outcome sitagliptin tecos eventdriven cardiovascular outcome study sitagliptin begin enrol patient tecos evaluate impact sitagliptin cardiovascular outcome add usual care compare usual care sitagliptin large highrisk type diabete population multiple country tecos expect complete quarter company expect result tecos present annual scientific meeting table content american diabetes association june result tecos trial negative effect cardiovascular outcome reveal safety issue relate use sitagliptin material adverse effect sale januvia janumetjanumet general medicine womens health worldwide sale nuvare vaginal contraceptive product million increase compare include unfavorable impact foreign exchange largely reflect high pricing united states global sale nuvare million increase compare primarily reflect volume growth favorable pricing united states worldwide sale implanonnexplanon singlerod subdermal contraceptive implant grow million compare drive primarily high demand united states implanonnexplanon sale increase million compare drive primarily volume growth united states partially offset decline emerge market pricing pressure global sale dulera inhalation aerosol combination medicine treatment asthma million million million reflect high demand united states dulera inhalation aerosol approve fda june global sales follistim market country outside united states puregon fertility treatment decline million compare drive largely low pricing united states low sale europe drive primarily volume decline sale follistim grow million compare drive largely positive performance united states patent provide market exclusivity follistim united states expire june august merck announce fda approve belsomra suvorexant treatment adult insomnia difficulty fall asleep andor stay asleep belsomra available united states early follow receipt marketing approval belsomra launch japan november company continue plan seek approval suvorexant country world april merck announce fda approve grastek ragwitek tablet sublingual use grastek allergen extract indicate immunotherapy treatment grass polleninduce allergic rhinitis conjunctivitis confirm positive skin test vitro test pollen specific ige antibodie timothy grass crossreactive grass pollen grastek approve use person year age ragwitek allergen extract indicate immunotherapy treatment short ragweed polleninduce allergic rhinitis conjunctivitis confirm positive skin test vitro test pollenspecific ige antibodie short ragweed pollen ragwitek approve use adult year age grastek ragwitek indicate immediate relief allergic symptom prescribe information grastek ragwitek include box warning severe allergic reaction grastek ragwitek ongoing phase program sublingual immunotherapy tablet allergic rhinitis associate house dust mite north america partnership merck alkabello hospital specialty hepatitis worldwide sale pegintron treatment chronic hcv million decline compare drive low volume region availability new therapeutic option result loss market share lead patient treatment delay market anticipate availability new therapeutic option foreign exchange unfavorably affect global sale performance global sale pegintron decline million compare reflect decline region attributable patient treatment delay health care provider anticipation new therapeutic option available foreign exchange unfavorably affect global sale performance global sale victrelis oral medicine treatment chronic hcv million decline compare drive low volume nearly region particularly united states availability new therapeutic option result loss market share lead patient treatment delay market anticipate availability new therapeutic option worldwide sale victrelis million decline compare include unfavorable effect foreign exchange sale decline table content united states europe canada partially offset growth emerge market sale decline united states europe canada attributable patient treatment delay health care provider anticipation new therapeutic option available sale company product indicate treatment chronic hcv include victrelis pegintron discuss rebetol continue adversely affect new therapeutic option available trend accelerate rapidly previously anticipate company addition development competitive hcv treatment market lead market share loss great company predict factor cause change cash flow projection pegintron victrelis rebetol indicate intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate pegintron victrelis rebetol compare related carry value result impairment charge million relate pegintron million relate victrelis million relate rebetol record material production cost sale product adversely affect patient treatment delay health care provider anticipation new therapeutic option available sale rebetol product sell entirely international market particularly adversely affect trend give market rebetol sell generic competition company record impairment charge million rebetol intangible asset event future circumstance arise significantly reduce current cash flow projection product company record additional intangible asset impairment charge future carrying value intangible asset relate product million aggregate december follow receipt market approval vanihep oral twicedaily protease inhibitor treatment chronic hcv launch japan november vanihep available japan hiv worldwide sale isentress hiv integrase inhibitor use combination antiretroviral agent treatment hiv infection increase billion compare primarily reflect volume growth europe emerge market particularly latin america result government tender partially offset volume decline united states reflect competitive pressure global sale isentress grow billion compare drive primarily volume growth united states europe foreign exchange unfavorably affect global sale performance acute care global sales cancidas antifungal product increase million compare largely reflect volume growth asia pacific region particularly china sale cancida increase million compare reflect growth emerge market europe japan worldwide sales noxafil prevention invasive fungal infection grow million increase million drive volume growth united states europe reflect positive impact approval new formulation bridion reversal type neuromuscular block agent surgery approve launch country outside united states sale bridion rise million compare drive volume growth market foreign exchange unfavorably affect global sale performance sale bridion million increase compare sale growth drive volume growth europe emerge market japan partially offset unfavorable effect foreign exchange primarily sale japan september company receive crl fda resubmission nda bridion address crl company conduct new hypersensitivity study october resubmitte nda fda company anticipate fda advisory committee meeting hold march review bridion approve company expect launch bridion united states later january merck acquire cubist leader development new therapy treat potentially lifethreatening infection cause broad range increasingly drugresistant bacteria cubist product include cubicin antibiotic complicated skin skin structure infection bacteremia cause table content designate susceptible organism zerbaxa combination product recently approve fda treatment adult complicated urinary tract infection cause designate susceptible gramnegative organism complicate intraabdominal infection cause designate susceptible gram negative grampositive organism sivextro treatment acute bacterial skin skin structure infection absssi adult cause designate susceptible grampositive organism zerbaxa sivextro review immunology sale remicade treatment inflammatory disease market company europe russia turkey billion increase compare reflect sale growth europe partially offset decline russia sale remicade billion increase compare include favorable effect foreign exchange sale growth reflect volume growth europe russia september approve infliximab biosimilar company experience biosimilar competition certain small european market company anticipate substantial decline remicade sale follow loss market exclusivity major european market february additionally company anticipate mandatory price reduction certain european market sale simponi oncemonthly subcutaneous treatment certain inflammatory disease market company europe russia turkey grow million compare drive demand europe reflect positive impact ulcerative colitis indication september approve simponi treatment adult patient moderately severely active ulcerative colitis inadequate response conventional therapy intolerant medical contraindication therapie sale simponi million compare million drive continued launch activity worldwide sale ophthalmic product cosopt trusopt decline million compare drive largely divestiture cosopt trusopt international market sale right cosopt cosopt discuss sale cosopt trusopt million decline compare reflect unfavorable effect foreign exchange low sale europe canada generic competition partially offset volume growth japan november merck sell right ophthalmic product cosopt cosopt azasite sale inspire pharmaceuticals inc subsidiary akorn inc akorn note merck enter agreement sell certain ophthalmic product include cosopt trusopt santen japan markets europe asia pacific transaction close market july remain market close october merck continue sell ophthalmic product market include transaction santen akorn merck sale saphris asenapine antipsychotic indicate treatment schizophrenia bipolar disorder adult million million million january merck sell marketing right saphris forest laboratories inc forest term agreement forest upfront payment million reflect sale additional payment merck base define sale milestone addition transaction merck agree supply product forest subsequently acquire actavis plc patent expiry asenapine sell brand sycrest approve treatment bipolar disorder adult commercialization agreement sycr sublingual tablet lundbeck make product supply payment exchange exclusive commercial right sycr market outside united states china japan company record impairment charge saphrissycrest intangible asset note consolidated financial statement product contain hospital specialty include invanz treatment certain infection primaxin antibacterial product oncology global sale emend prevention chemotherapyinduce postoperative nausea vomit million increase compare include unfavorable effect foreign exchange largely reflect volume growth region sale emend million increase table content compare include unfavorable effect foreign exchange largely reflect volume growth united states emerge market partially offset decline japan sale temodar market temodal outside united states treatment certain type brain tumor decline million decrease million foreign exchange unfavorably affect global sale performance sale decline drive primarily generic competition united states europe previously disclose agreement generic manufacturer launch generic version temodar united states august patent exclusivity period expire february temodar lose patent exclusivity accordingly company experience sale decline loss exclusivity market company expect decline continue september merck announce fda grant accelerated approval keytruda dose mgkg week treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor keytruda antipd program death receptor therapy approve united states june merck announce european medicine agency ema accept review marketing authorization application maa keytruda treatment advanced melanoma company additional regulatory filing country filing plan december company estimate patient receive treatment keytruda sale keytruda million keytruda clinical development program include study broad range cancer type research development october keytruda grant breakthrough therapy designation fda treatment patient epidermal growth factor receptor mutation negative anaplastic lymphoma kinase rearrangementnegative nonsmallcell lung cancer disease progress follow platinumbase chemotherapy company anticipate submit sbla fda mid keytruda diversified brand mercks diversify brand include human health pharmaceutical product approach expiration marketing exclusivity long protect patent develop market continue core company offer market world respiratory global sale nasonex inhale nasal corticosteroid treatment nasal allergy symptom decline billion compare foreign exchange unfavorably affect global sale performance sale decline drive primarily low demand united states low volume europe canada generic competition agreement generic manufacturer able launch generic version nasonex european market january generic version nasonex launch market accordingly company experience rapid decline nasonex sales europe expect decline continue sale nasonex increase billion compare drive primarily increase united states reflect net favorable adjustment indirect customer discount volume growth japan partially offset decline latin america canada europe foreign exchange unfavorably affect global sale performance apotex inc apotex corp collectively apotex file application fda seek approval sell generic version nasonex june district court district new jersey rule company patent infringement suit apotex hold apotexs generic version nasonex infringe company formulation patent june court appeal federal circuit issue decision affirm district court decision company exhaust appeal option apotexs generic version available significant loss nasonex sale occur company noncash impairment charge respect carry value nasonex intangible asset million december nasonex intangible asset determine impaired impairment charge material sale nasonex million worldwide sale singulair onceaday oral medicine chronic treatment asthma relief symptom allergic rhinitis billion decline compare include unfavorable effect foreign exchange primarily reflect low sale europe result generic competition table content patent provide market exclusivity singulair expire number major european market february company experience significant rapid decline sale singulair market follow patent expiry expect decline continue global sale singulair fall billion compare drive primarily low sale united states europe result generic competition patent provide market exclusivity singulair expire august patent provide market exclusivity singulair japan expire singulair sale japan million global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension decline million decrease billion foreign exchange unfavorably affect global sale performance respectively patent provide market exclusivity cozaar hyzaar united states major international market expire accordingly company experience significant decline cozaar hyzaar sale expect decline continue worldwide sale fosamax market fosamac japan fosamax plus market fosavance treatment case fosamax prevention osteoporosis decrease million decline million drive decline region medicine lose market exclusivity united states major international market company expect sale decline fosamax product franchise continue product contain diversified brand include clarinex nonsedate antihistamine arcoxia treatment arthritis pain propecia product treatment male pattern hair loss zocor statin modifying cholesterol remeron antidepressant vaccine follow discussion vaccine include sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate select joint venture affiliate information supply sale spmsd include merck sale gardasil vaccine help prevent certain disease cause type hpv billion decline compare include unfavorable effect foreign exchange decline reflect low sale asia pacific japan canada partially offset high government tender brazil national immunization program high public sector purchase united states merck sale gardasil grow billion compare drive primarily volume growth united states reflect continued uptake male female volume growth latin america partially offset low volume japan sale include million million million respectively purchase center disease control prevention cdc pediatric vaccine stockpile june japanese health ministry issue advisory suspend active promotion hpv vaccine company party certain thirdparty license agreement respect gardasil include cross license settlement agreement glaxosmithkline result agreement company pay royalty worldwide gardasil sale vary country include material production cost december company announce fda approve gardasil merck valent hpv vaccine use girl young woman year age prevention cervical vulvar vaginal anal cancer cause hpv type precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil approve use boy year age prevention anal cancer cause hpv type precancerous dysplastic lesion cause hpv type genital wart cause hpv type gardasil include great number hpv type available hpv vaccine merck sale proquad pediatric combination vaccine help protect measle mump rubella varicella million million million increase compare drive primarily high sale united states reflect approximately million government purchase cdc pediatric vaccine stockpile sale proquad affect supply constraint proquad available united states order october table content merck sale varivax vaccine help prevent chickenpox varicella million million million sale performance reflect low sale united states largely offset growth emerge market merck sale mmr vaccine help protect measle mump rubella million million million sale varivax mmr decline compare availability proquad discuss merck sale zostavax vaccine help prevent shingles herpe zoster adult year age old million increase compare drive primarily high sale asia pacific region ongoing launch partially offset low demand united states canada company continue educate customer broad manage care coverage zostavax process obtain reimbursement merck sale zostavax grow million compare drive high demand united states canada launch asia pacific region merck continuing launch zostavax outside united states mercks sale pneumovax vaccine help prevent pneumococcal disease grow million compare drive primarily high sale japan national immunization program high sale united states attributable price volume foreign exchange unfavorably affect sale performance merck sale pneumovax increase million compare drive primarily volume growth emerge market volume price increase united states mercks sale rotateq vaccine help protect rotavirus gastroenteritis infant child increase million compare primarily reflect high sale certain emerge market merck sale rotateq grow million compare reflect high pricing united states volume growth japan segment company segment animal health alliance segment material separate report prior disposition october company consumer care segment animal health animal health include pharmaceutical vaccine product prevention treatment control disease major farm companion animal species animal health sale affect competition frequent introduction generic product global sale animal health product total billion growth compare include unfavorable effect foreign exchange sale growth drive primarily high sale companion animal product reflect launch bravecto europe united states high sale poultry aqua product partially offset low sale zilmax august merck animal health voluntarily suspend sale zilmax feed supplement beef cattle united states canada merck announce fda approve bravecto chewable tablet dog treat flea tick bravecto treatment show quickly effectively kill flea multiple tick specie weeks single dose bravecto effective week amblyomma americanum tick addition bravecto approve launch approximately country outside united states global sale animal health product billion decline compare include unfavorable effect foreign exchange sale decline reflect low sale ruminant product primarily zilmax partially offset growth companion animal poultry product suspension zilmax unfavorably affect animal health sale alliance alliance segment include result company relationship azlp june astrazeneca exercise option buy merck interest subsidiary merck interest nexium prilosec result july company long record equity income azlp supply sale azlp primarily relate sale nexium prilosec terminate select joint venture table content affiliate information revenue azlp primarily relate sale nexium prilosec million termination date june million million consumer care note october company divest consumer care segment consumer care product include overthecounter foot care sun care product global sale consumer care billion billion billion cost expense million change change material production marketing administrative research development restructuring cost equity income affiliate income expense net great include million million million iprd impairment charge respectively material production material production cost billion billion billion cost include expense amortization intangible asset record connection merger acquisition total billion billion billion cost include intangible asset impairment charge billion million respectively relate marketed product note consolidated financial statement company recognize additional noncash impairment charge future relate product intangible measure fair value capitalize connection merger acquisition charge material additionally cost include million intangible asset impairment charge relate licensing agreement include material production cost associate restructuring activity amount million million million respectively include accelerate depreciation asset writeoff relate plan sale closure manufacturing facility separation cost associate manufacturingrelate headcount reduction incur reflect restructure cost discuss gross margin compare amortization intangible asset restructure impairment charge note reduce gross margin percentage point percentage point percentage point exclude impact gross margin decline compare drive primarily unfavorable effect inventory writeoff largely relate victreli change product mix partially offset sale marketing right saphris gross margin decline compare drive loss singulair sale result patent expiry united states august major european market february addition generic competition united states couple change product mix continue pricing pressure mature market negatively affect gross margin compare market administrative marketing administrative expense decline billion drive primarily low selling cost promotional spending divestiture mcc favorable effect foreign exchange partially offset additional year expense relate health care reform fee discuss high acquisition divestiturerelated cost market administrative expense decrease billion largely low promotional spending selling cost result restructuring activity reflect favorable effect foreign exchange expense include restructure cost million million million respectively relate primarily accelerate depreciation facility close table content divest separation cost associate sale force reduction incur reflect restructure cost discuss expense include million million million acquisition divestiturerelated cost respectively consist incremental thirdparty integration cost relate merger include cost relate legal entity system integration transaction certain cost relate business acquisition divestiture july irs issue final regulation annual nontax deductible health care reform fee impose patient protection affordable care act base allocation company market share prior year brand pharmaceutical sale certain government program final irs regulation accelerate recognition criterion fee obligation year year underlie sale allocate fee occur year fee pay result change merck record additional year expense million research development research development expense billion billion billion research development expense comprise cost directly incur merck research laboratory mrl company research development division focus human health relate activity approximately billion billion billion include research development expense cost incur division support research development activity include depreciation production general administrative licensing activity certain cost operate segment include pharmaceutical animal health segment consumer care segment divestiture october aggregate billion billion billion respectively cost include million charge relate collaboration bayer note consolidated financial statement decline research development cost drive cost saving result restructure activity target reduction low clinical development spend result portfolio prioritization decline research development expense compare reflect low payment license activity research development expense include acquire inprocess research development iprd impairment charge million million million respectively research development company recognize additional noncash impairment charge future cancellation delay pipeline program measure fair value capitalize connection merger acquisition charge material company record charge million increase estimate fair value liability contingent consideration relate research project obtain connection acquisition business prior year note consolidated financial statement research development expense reflect million million million respectively accelerate depreciation asset abandonment cost associate restructuring activity restructure cost restructure cost primarily represent separation relate cost associate restructuring activity billion billion million respectively cost include million million respectively cost related restructuring program remain cost nearly remain cost record cost record related merger restructuring program separation cost million billion million respectively incur associate actual headcount reduction estimate expense exist severance program headcount reduction probable reasonably estimate position eliminate restructure program approximately position eliminate merger restructuring program approximately position elimination comprise actual headcount reduction elimination contractor vacant position include restructuring cost asset abandonment shutdown relate cost employee relate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation plan cost segment report restructuring cost unallocated expense additional cost associate company restructuring activity include material production marketing administrative research development discuss table content equity income affiliate equity income affiliate reflect performance company joint venture equity method affiliate decline million compare decline drive primarily termination company relationship azlp discuss june astrazeneca exercise option purchase merck interest subsidiary merck interest nexium prilosec effective july company long record equity income azlp select joint venture affiliate information equity income affiliate decline million compare drive primarily low equity income azlp partially offset high equity income spmsd income expense net income expense net billion income compare million expense drive primarily gain recognize include billion gain relate divestiture mcc note consolidated financial statement million gain relate astrazenecas option exercise note consolidated financial statement million gain sale certain ophthalmic product international market note consolidated financial statement million gain relate divestiture sirna note consolidated financial statement low exchange loss venezuelan currency devaluation note consolidated financial statement partially offset favorability item million loss extinguishment debt note consolidated financial statement million goodwill impairment charge relate company joint venture supera note consolidated financial statement income expense net million expense compare billion expense reflect million net charge relate settlement certain shareholder litigation enhance litigation partially offset high exchange loss drive million exchange loss relate venezuelan currency devaluation high interest expense result issuance debt september segment profit million pharmaceutical segment profit nonreportable segment profit income income taxis segment profit comprise segment sale standard cost certain operating expense directly incur segment component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit acquisition divestiturerelated cost include amortization purchase accounting adjustment intangible asset impairment charge restructure cost taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item include gain divestiture include mcc gain astrazenecas option exercise loss extinguishment debt additional year expense relate health care reform fee charge record relate settlement enhance litigation reflect table include miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale pharmaceutical segment profit decline compare drive primarily unfavorable effect product divestiture loss market exclusivity certain product partially offset cost saving productivity measure pharmaceutical segment profit decline compare drive primarily effect loss market exclusivity certain product particularly singulair decline segment table content profit compare drive primarily termination company relationship azlp divestiture mcc taxis income effective income tax rate reflect impact acquisition divestiturerelated cost restructure cost partially offset beneficial impact foreign earning effective income tax rate reflect impact gain divestiture mcc tax combine federal state tax rate effective income tax rate include net tax benefit million record connection astrazenecas option exercise note consolidated financial statement benefit approximately million associate capital loss generate connection sale sirna note consolidated financial statement effective income tax rate include unfavorable impact additional year expense nontax deductible health care reform fee company record accordance final regulation issue quarter irs effective tax rate reflect net benefit million settlement certain federal income tax issue net benefit reduction tax reserve expiration applicable statute limitation favorable impact tax legislation enact quarter extend tax credit outofperiod net tax benefit approximately million associate resolution previously disclose legacy scheringplough federal income tax issue note consolidated financial statement effective tax rate reflect favorable impact tax settlement canada revenue agency cra realization foreign tax credit impact favorable rule state tax matter addition effective tax rate reflect unfavorable impact net charge record connection settlement enhance litigation tax benefit record reflect impact tax credit expire december result legislation pass extend tax credit tax credit recognize note net income attributable noncontrolle interest net income attributable noncontrolle interest million million million decline reflect termination company relationship azlp note consolidated financial statement addition include portion intangible asset goodwill impairment charge relate company joint venture supera attributable noncontrolle interest net income earning common share net income attributable merck inc billion billion billion eps increase net income ep compare primarily gain divestiture mcc gain recognize astrazenecas option exercise gain divestiture low operating expense high favorability discrete tax item revenue recognize sale marketing right saphris partially offset low sale loss extinguishment debt high intangible asset impairment charge additional year expense health care reform fee decline net income ep compare primarily low sale reflect loss market exclusivity certain product particularly singulair high restructuring cost intangible asset impairment charge exchange loss partially offset favorable impact certain tax item low operating expense nongaap income nongaap ep nongaap income nongaap eps alternative view company performance management merck provide management believe information enhance investor understand company result nongaap income nongaap eps exclude certain item nature item impact analysis underlie business performance trend exclude item consist acquisition divestiturerelate cost restructure cost certain item exclude item significant component understand assess financial performance information nongaap income nongaap eps consider addition lieu net income ep prepared accordance generally accept accounting principle united states gaap additionally nongaap income nongaap ep measure determine accordance gaap standardize table content mean prescribed gaap comparable calculation similar measure company nongaap income nongaap ep important internal measure company senior management receive monthly analysis operating result include nongaap income nongaap ep performance company measure basis performance metric senior management annual compensation derive nongaap income nongaap ep reconciliation gaap financial measure nongaap financial measure follow million share amount pretax income report gaap increase decrease exclude item acquisition divestiturerelated cost restructure cost item gain divestiture merck consumer care gain astrazeneca option exercise gain divestiture certain ophthalmic product loss extinguishment debt additional year expense health care reform fee net charge relate settlement enhance litigation taxis income report gaap estimate tax provision benefit exclude item tax benefit relate sale sirna therapeutics inc subsidiary net tax benefit settlement federal income tax issue nongaap net income net income attributable noncontrolle interest report gaap acquisition divestiturerelate cost attributable noncontrolle interest nongaap net income attributable merck inc eps assume dilution report gaap ep difference nongaap ep assume dilution include net benefit million record connection astrazeneca option exercise represent difference calculate gaap ep calculate nongaap eps different calculate dividing impact exclude item weightedaverage share applicable year acquisition divestiturerelate cost nongaap income nongaap eps exclude impact certain amount record connection merger acquisition divestiture amount include amortization intangible asset intangible asset impairment charge expense income relate change fair value measurement contingent consideration exclude incremental thirdparty integration cost associate merger cost relate legal entity system integration transaction certain cost associate business acquisition divestiture cost consider non recur management exclude amount table content nongaap income nongaap eps believe helpful understanding performance continue business restructuring cost nongaap income nongaap eps exclude cost relate restructuring action note consolidated financial statement amount include employee separation cost accelerate depreciation associate facility close divested accelerated depreciation cost represent difference depreciation expense recognize revise useful life site base anticipate date site close divest depreciation expense determine utilize useful life prior restructure action restructure cost include asset abandonment shut relate cost employeerelate cost curtailment settlement termination charge associate pension postretirement benefit plan sharebase compensation cost company undertake restructuring different type cover period charge consider nonrecurre management exclude amount nongaap income nongaap eps believe helpful understanding performance continue business certain item nongaap income nongaap eps exclude certain item item represent substantive unusual item evaluate individual basis evaluation consider quantitative qualitative aspect unusual nature generally represent item result nature magnitude management anticipate occur company normal business regular basis certain item comprise gain divestiture mcc gain recognize conjunction astrazeneca option exercise include related net tax benefit transaction gain divestiture certain ophthalmic product international market loss extinguishment debt additional year expense relate health care reform fee tax benefit sale sirna tax benefit settlement certain federal income tax issue net charge record connection settlement enhance litigation research development chart reflect company current research pipeline february set forth item business research development research development update company currently candidate regulatory review united states internationally keytruda antipd program death receptor therapy review ema treatment advanced melanoma september fda approve keytruda dose mgkg week treatment patient unresectable metastatic melanoma disease progression follow ipilimumab braf mutation positive braf inhibitor keytruda antipd therapy approve united states keytruda clinical development program include study cancer type include bladder colorectal gastric head neck melanoma nonsmallcell lung renal triple negative breast hematological malignancy addition company announce number collaboration pharmaceutical company evaluate novel combination regimen keytruda october keytruda grant breakthrough therapy designation fda treatment patient epidermal growth factor receptor mutationnegative anaplastic lymphoma kinase rearrangementnegative non smallcell lung cancer disease progress follow platinumbase chemotherapy company anticipate submit sbla fda mid keytruda bridion investigational agent reversal neuromuscular blockade induce rocuronium vecuronium neuromuscular block agent neuromuscular blockade anesthesiology induce muscle relaxation surgery september merck announce receive crl fda resubmission nda bridion address crl company conduct new hypersensitivity study october resubmitte nda fda company anticipate fda advisory committee table content meeting hold march review bridion approve company expect launch bridion united states later bridion approve launch country outside united states dtapipvhibhepb investigational pediatric hexavalent vaccine company develop partnership sanofi pasteur review fda ema approvedv pediatric combination vaccine united states design help protect important disease diphtheria tetanus pertussis whooping cough polio poliovirus type invasive disease cause haemophilus influenzae type hib hepatitis approve copromote united states partnership sanofi pasteur market spmsd joint venture europe omarigliptin investigational onceweekly dpp inhibitor development treatment type diabete november merck announce company submit new drug application omarigliptin japanese pharmaceutical medical devices agency omarigliptin phase clinical development united states sivextro oncedaily oxazolidinone antibiotic develop intravenous oral administration treatment abssi cause certain grampositive organism review ema january merck announce committee medicinal product human use chmp ema adopt positive opinion recommend approval sivextro treatment absssi adult merck acquire sivextro purchase cubist affirm chmp opinion grant centralized marketing authorization unify labeling valid country member european economic area member iceland liechtenstein norway sivextro approve united states indicate treatment adult absssi cause designate susceptible grampositive organism company conduct phase clinical trial assess safety efficacy sivextro adult patient ventilate nosocomial pneumonia include ventilatorassociate bacterial pneumonia vabp ventilate hospitalacquire bacterial pneumonia ventilate habp fda designate sivextro qualified infectious disease product qidp approve indication absssi potential indication ventilate nosocomial pneumonia include vabp ventilate habp oral dosage form mka zerbaxa combination product treatment certain bacterial infection adult review ema merck acquire zerbaxa purchase cubist december zerbaxa approve fda treatment adult complicated urinary tract infection cause designate susceptible gramnegative organism complicate intraabdominal infection cause designate susceptible gramnegative grampositive organism company conduct phase clinical trial assess safety efficacy zerbaxa adult patient ventilate nosocomial pneumonia include vabp ventilate habp fda designate zerbaxa qidp approve indication potential indication ventilate nosocomial pneumonia include vabp ventilate habp gardasil company ninevalent hpv vaccine help protect certain hpvrelate disease review ema incorporate antigen additional cancercause hpv type compare gardasil gardasil approve fda december corifollitropin alfa injection investigational fertility treatment review fda control ovarian stimulation woman participate assist reproductive technology july merck receive crl fda nda corifollitropin alfa injection merck review option respect drug candidate response crl corifollitropin alfa injection market elonva certain market outside united states addition candidate regulatory review company drug candidate phase development company anticipate file nda bla applicable fda respect certain candidate mka daily fixeddose combination chronic hcv treatment regimen consist grazoprevir investigational hcv nsa protease inhibitor elbasvir investigational hcv nsa replication complex inhibitor begin phase clinical trial june mka investigate broad clinical program include study patient multiple hcv genotype treatmentnave treatment failure fit important hcv subpopulation patient cirrhosis coinfecte hiv company expect file nda fda half mka january table content company receive notification fda intent rescind breakthrough therapy designation status combination treatment regimen cite availability recently approve treatment genotype patient company discuss matter fda expect impact ability file nda combination regiman time filing company start phase ccr study study combination regimen grazoprevir idx elbasvir treatment hcv infection company expect begin phase study odanacatib oral onceweekly investigational treatment patient osteoporosis osteoporosis disease reduce bone density strength result increase risk bone fracture odanacatib cathepsin inhibitor selectively inhibit cathepsin enzyme cathepsin know play central role function osteoclast cell break exist bone tissue particularly protein component bone inhibition cathepsin novel approach treatment osteoporosis september merck announce datum pivotal phase fracture outcomes study odanacatib postmenopausal woman osteoporosis longterm odanacatib fracture trial loft odanacatib meet primary endpoint significantly reduce risk type osteoporotic fracture radiographicallyassesse vertebral clinical hip clinical nonvertebral compare placebo reduce risk secondary endpoint clinical vertebral fracture addition treatment odanacatib lead progressive increase year bone mineral density lumbar spine total hip rate adverse event overall loft generally balanced patient take odanacatib placebo adjudicate event morphealike skin lesion atypical femoral fracture occur odanacatib group placebo group adjudicate major adverse cardiovascular event generally balance overall treatment group numerically adjudicate stroke event odanacatib placebo adjudicate atrial fibrillation report odanacatib group placebo group numeric imbalance mortality observe numeric difference appear related particular reported cause cause death merck continue collect datum blind extension study plan additional analysis datum trial include independent readjudication major adverse cardiovascular event support regulatory submission merck plan submit nda fda odanacatib merck plan submit application ema ministry health labour welfare japan investigational allergy immunotherapy tablet house dust mite allergy fda approve grastek timothy grass pollen allergen extract sublingual immunotherapy tablet ragwitek short ragweed pollen allergen extract sublingual immunotherapy tablet grastek ragwitek ongoing program north america partnership merck alkabello merck novel investigational oral amyloid precursor protein sitecleave enzyme bace inhibitor treatment alzheimer disease study phase trial apec design evaluate safety efficacy versus placebo patient amnestic mild cognitive impairment alzheimer disease know prodromal alzheimer disease study phase trial versus placebo patient mildtomoderate alzheimer disease epoch anacetrapib investigational inhibitor cholesteryl ester transfer protein cetp development raise hdlc reduce ldlc anacetrapib evaluate large eventdriven cardiovascular clinical outcome trial reveal randomize evaluation effect anacetrapib lipidmodification involve patient preexist vascular disease predict complete mka actoxumabbezlotoxumab investigational candidate prevention clostridium difficile infection recurrence combination monoclonal antibody treat patient single infusion surotomycin investigational oral antibiotic development treatment clostridium difficile associate diarrhea merck acquire surotomycin purchase cubist fda designate surotomycin qidp letermovir investigational oral oncedaily antiviral candidate prevention treatment human cytomegalovirus infection letermovir receive orphan drug status united states grant fast track designation table content ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabete collaboration pfizer inc insulin glargine candidate treatment patient type type diabetes february company announce expand collaboration samsung bioepis develop manufacture commercialize term agreement company collaborate clinical development regulatory filing manufacture approve merck commercialize candidate inactivated varicella zoster virus vaccine development prevention herpe zoster company conduct phase trial autologous hematopoietic cell transplant patient patient solid tumor malignancy undergo chemotherapy hematological malignancy doravirine investigational oncedaily oral nextgeneration nonnucleoside reverse transcriptase inhibitor develop merck treatment hiv infection bevenopran oral investigational therapy development potential treatment opioidinduce constipation patient chronic noncancer pain merck acquire bevenopran purchase cubist september merck sun pharmaceutical industries ltd sun pharma enter exclusive worldwide licensing agreement merck investigational therapeutic antibody candidate tildrakizumab treatment chronic plaque psoriasis skin ailment term agreement sun pharma acquire worldwide right tildrakizumab use human indication merck exchange upfront payment million merck continue clinical development regulatory activity fund sun pharma product approval sun pharma responsible regulatory activity include subsequent submission pharmacovigilance post approval study manufacturing commercialization approve product merck eligible receive future payment associate regulatory include product approval sale milestone tiere royalty range midsingle digit teen percentage rate sale merck endocyte inc endocyte company collaboration partner announce withdrawal conditional maa ema vintafolide treatment adult patient folate receptorpositive platinumresistant ovarian cancer combination pegylate liposomal doxorubicin pld company decision base review interim datum proceed trial proceed trial terminate base datum safety monitoring board dsmb recommendation study stop vintafolide combination pld versus pld meet prespecifie criterion progressionfree survival allow continuation study dsmb identify safety concern patient enrol proceed trial june merck return worldwide right vintafolide indication endocyte company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development model design increase productivity improve probability success prioritize company research development resource candidate company believe capable provide unambiguous promotable advantage patient payer deliver maximum value approve medicine vaccine new indication new formulation merck pursue emerge product opportunity independent therapeutic area modality small molecule biologic vaccine build biologics capability merck move diversify portfolio collaboration development biosimilar potential harness market opportunity present biological medicine patent expiry deliver high quality biosimilar enhance access patient worldwide company commit make externally source program great component pipeline strategy renew focus supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology company review pipeline examine candidate provide value outlicense company evaluate certain latestage clinical development platform technology asset determine outlicense sale potential table content company clinical pipeline include candidate multiple disease area include atherosclerosis cancer cardiovascular disease diabete infectious disease inflammatoryautoimmune disease neurodegenerative disease osteoporosis respiratory disease womens health acquire inprocess research development connection merger acquisition company record fair value inprocess research project time acquisition reach technological feasibility december balance iprd billion majority relate clinical development program company acquire acquisition idenix discuss significant project latestage development include company bace inhibitor bridion discuss approximately million million million respectively iprd project receive marketing approval major market company begin amortize asset base estimate useful life iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate time period receive approval fda regulatory agency subject uncertainty significant delay approval process company failure obtain approval delay prevent company realize revenue product additionally certain iprd program fail abandon development company realize future cash flow estimate record iprd acquisition date company recover research development expenditure acquisition develop program circumstance occur company future operating result adversely affect company recognize impairment charge charge material company record million iprd impairment charge research development expense primarily result change cash flow assumption certain compound obtain connection supera joint venture discontinuation certain animal health program company record million iprd impairment charge million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program previously deprioritize subsequently deem alternative use period additional research development require remain program reach technological feasibility cost complete research project depend project bring final stage development ultimately submit fda regulatory agency approval december estimate cost complete project acquire connection merger acquisition phase development human health analogous stage development animal health approximately billion acquisition research collaboration license agreement merck continue remain focused pursue opportunity potential drive near longterm growth certain significant transaction describe merck actively monitor landscape growth opportunity meet company strategic criterion august merck complete acquisition idenix approximately billion cash billion net cash acquire idenix biopharmaceutical company engage discovery development medicine treatment human viral disease primary focus development nextgeneration oral antiviral therapeutic treat hcv infection transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption merck recognize intangible asset iprd billion related idx net defer tax table content liabilitie million net asset liability approximately million nucleotide prodrug phase clinical development evaluate potential inclusion development oral pangenotypic fixeddose combination regimen excess consideration transfer fair value net asset acquire billion record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate transaction close august accordingly result operation acquire business include company result operation begin date pro forma financial information include idenixs historical financial result significant compare company financial result october company enter worldwide clinical development collaboration bayer market develop portfolio soluble guanylate cyclase sgc modulator include bayers adempas riociguat member novel class compound adempas approve treat pulmonary arterial hypertension pah drug treatment approve patient chronic thromboembolic pulmonary hypertension cteph adempas currently market united states europe pah cteph japan cteph company equally share cost profit collaboration implement joint development commercialization strategy collaboration include clinical development bayer vericiguat currently phase trial worsen heart failure optin right earlystage sgc compound development bayer merck turn available earlystage sgc compound similar term return broad collaboration right merck upfront payment bayer billion potential additional milestone payment achievement agreedupon sale goal adempas bayer continue lead commercialization america merck lead commercialization rest world vericiguat potential optin product bayer lead rest world merck lead america product candidate include agreement company share development cost profit sale right copromote territory lead company determine merck payment access bayer compound constitute acquisition asset billion consideration pay merck million fair value relate currently market product adempas capitalize intangible asset subject amortization estimate useful life year remain million fair value relate vericiguat compound currently clinical development expense research development expense fair value adempas vericiguat determine income approach fair value estimate base probability adjust future net cash flow vericiguat stage development project associate probability successful completion net cash flow discount present value discount rate adempas vericiguat future sale base milestone accrue probable reasonably estimable company bayer right terminate agreement cause productbyproduct basis product develop commercialize agreement adempas bayer termination right event party material uncured breach relate product december merck acquire oncoethix privately hold biotechnology company specialize oncology drug development total purchase consideration transaction million include upfront cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve company determine fair value million acquisition date transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption merck recognize intangible asset iprd million relate otx investigational novel oral bet bromodomain inhibitor currently phase study treatment hematological malignancy advance solid tumor liability contingent consideration million net asset liability million fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate fair value contingent consideration determine utilize probability weight estimate cash flow stream adjust expect timing payment table content utilize discount rate transaction close december accordingly result operation acquire business include company result operation begin date pro forma financial information include oncoethixs historical financial result significant compare company financial result december merck cubist announce definitive agreement merck acquire cubist total purchase price approximately billion cubist leader development new therapy treat potentially lifethreatening infection cause broad range increasingly drugresistant bacteria transaction close january accordingly result operation acquire business include company result operation begin date addition february merck ngm biopharmaceuticals inc ngm privatelyheld biotechnology company announce enter multiyear collaboration research discover develop commercialize novel biologic therapy wide range therapeutic area collaboration include multiple drug candidate currently preclinical development ngm include evaluate treatment diabete obesity nonalcoholic steatohepatitis ngm lead research development exist preclinical candidate autonomy identify pursue discovery stage program discretion merck option license result ngm program follow human proof concept trial merck exercise option merck lead global product development commercialization result product approve term agreement merck upfront payment ngm million purchase equity stake ngm million merck commit million fund ngms effort initial fiveyear term collaboration potential additional funding certain condition meet prior merck initiate phase study license program ngm elect receive milestone royalty payment certain case cofund development participate global cost revenue share arrangement agreement provide ngm option participate copromotion cofunde program united states merck option extend research agreement additional twoyear term agreement effective expiration waiting period hartscottrodino antitrust improvement act select joint venture affiliate information astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right merck earn revenue base sale kbi product revenue million million million respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest return aggregate million million million respectively june astrazeneca exercise option purchase merck interest kbi million cash million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june defer recognize time income expense net contingency eliminate sale occur remain exercise price million primarily represent multiple time table content merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net result astrazenecas option exercise company remain interest azlp redeem accordingly company recognize noncash gain approximately million income expense net result retirement billion kbi prefer stock note consolidated financial statement elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance result astrazeneca exercise option july company long record equity income azlp supply sale azlp terminate sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe sale joint venture product follow million gardasil influenza vaccine zostavax viral vaccine rotateq hepatitis vaccine vaccine capital expenditure capital expenditure billion billion billion expenditure united states million million billion depreciation expense billion billion billion billion billion billion respectively apply location united states total depreciation expense include accelerate depreciation million million million respectively associate restructuring activity note consolidated financial statement analysis liquidity capital resource merck strong financial profile enable fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder select datum millions work capital total debt total liability equity cash provide operation total debt cash provide operating activity billion billion billion decline cash provide operating activity compare reflect approximately billion taxis pay divestiture mcc cash provide operating activity include payment company million connection previously disclose settlement enhance litigation cash provide operating activity reflect high contribution define benefit plan compare cash provide operating activity include payment million relate resolution certain litigation relate vioxx cash provide operating activity continue company primary source fund finance operating need capital expenditure portion treasury stock purchase table content dividend pay shareholder global economic condition ongoing sovereign debt issue factor adversely affect foreign receivables certain european country note consolidated financial statement cash investing activity million compare billion reflect cash receive divestiture mcc disposition business primarily relate transaction aspen santen note consolidated financial statement cash receive connection astrazenecas option exercise note consolidated financial statement partially offset high purchase low proceed sale security investment cash acquisition idenix note consolidated financial statement cash payment formation collaboration bayer note consolidated financial statement cash investing activity billion compare billion primarily reflect high proceed sale security investment low capital expenditure partially offset high purchase security investment cash financing activity billion compare billion drive primarily high payment debt low proceed issuance debt high purchase treasury stock decrease shortterm borrowing partially offset high proceed exercise stock option cash financing activity billion compare billion high use cash financing activity drive primarily high purchase treasury stock high payment debt decrease shortterm borrowing partially offset high proceed issuance debt december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment generally cash investment hold foreign subsidiary subject significant tax payment cash investment repatriate form dividend company record defer tax liability certain unremitte earning amount earn overseas expect indefinitely reinveste outside united states accrual taxis provide cash investment hold foreign subsidiary fluctuate variety factor include time receipt payment normal course business cash provide operating activity united states continue company primary source fund finance domestic operating need capital expenditure portion treasury stock purchase dividend pay shareholder company contractual obligation december follow payment period million total purchase obligation loan payable current portion longterm debt longterm debt interest relate debt obligation unrecognize tax benefit operating lease include future bulk supply purchase company commit connection certain divestiture include disposition api manufacturing business discuss amount reflect debt interest payment relate company february debt issuance discuss december company consolidated balance sheet reflect liability unrecognize tax benefit interest penalty billion include billion reflect current liability high degree uncertainty time future cash outflow liability unrecognize tax benefit year reasonable estimate period cash settlement year purchase obligation enforceable legally bind obligation purchase good service include minimum inventory contract research development advertising amount reflect research development obligation include contingent milestone payment exclude research table content development obligation potential future funding commitment approximately million investment research venture capital fund loan payable current portion longterm debt reflect million longdate note subject repayment option holder require funding obligation relate company pension postretirement benefit plan expect material company currently anticipate contribute approximately million pension plan million international pension plan million postretirement benefit plan august company terminate exist credit facility enter new billion fiveyear credit facility mature august facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility october company issue eurodenominate senior unsecured note consist billion principal note billion principal note million principal note interest note payable annually note series redeemable time company option vary redemption price net proceed offer billion repay debt validly tender connection tender offer launch company certain outstanding note debenture company pay billion aggregate consideration applicable purchase price accrue interest redeem billion principal debt addition november merck redeem billion note billion note february merck issue billion aggregate principal senior unsecured note consist million principal float rate note million principal float rate note billion principal note billion aggregate principal note billion aggregate principal note billion aggregate principal note company substantial portion net proceed offer repay commercial paper issue substantially finance company acquisition cubist remain net proceed general corporate purpose include limitation repurchase company common stock repayment outstanding commercial paper borrowing upcoming debt maturity december company enter bridge loan agreement certain bank pursuant company ability borrow billion purpose obtain shortterm financing acquisition cubist company borrow fund bridge loan issue billion senior unsecured note discuss terminate bridge loan february december company file security registration statement securities exchange commission sec automatic shelf registration process available wellknown seasoned issuer effective year effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date company longterm credit rating assign moodys investor service standard poor stable outlook stable outlook respectively rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile company place cash investment instrument meet high credit quality standard specify investment policy guideline guideline limit credit exposure issuer despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation november board director declare quarterly dividend share company common stock payable january table content company announce board director authorize additional purchase billion merck common stock treasury purchase openmarket transaction block transaction exchange privately negotiate transaction company purchase billion common stock million share treasury company approximately billion remain share repurchase program company purchase billion billion common stock respectively previously authorize share repurchase program financial instrument market risk disclosure company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow weak dollar result net benefit market value merck hedge decline estimate million million december respectively uniform weaken dollar market value determine foreign table content exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level cash flow contract report operating activity consolidate statement cash flow sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly strengthen currency exposure company december income taxis decline approximately million million company net long position relative major foreign currency consideration forward contract uniform strengthen dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow february venezuelan government devalue currency bolvar fuerte vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation march venezuelan government announce creation new foreign exchange mechanism call complimentary system foreign currency acquirement know sicad operate similar auction system allow entity specific sector bid dollar payment relate international investment certain intangible march venezuelan government launch foreign exchange mechanism know sicad indicate industry sector able access sicad use restrict purpose sicad sicad average rate publish central bank venezuela december average exchange rate infer vef dollar vef dollar respectively sicad sicad eliminate change official rate vef dollar december company approximately million dollar equivalent official rate net monetary asset venezuelan entity large majority cash company receive approximately million venezuela transaction settle official rate vef dollar approximately million pende approval future settlement official rate february venezuelan government announce sicad replace sistema marginal divisas know simadi simadi market intend operate base principle supply demand buyer seller exchange offer transact accord venezuelan central bank average exchange rate day trading february vef dollar sicad mechanism remain unchanged recent announcement venezuelan government indicate essential good include food medicine remain official rate vef dollar company table content sicad mechanism settle transaction anticipate sicad simadi mechanism settle transaction accordingly company conclude appropriate continue use official rate vef dollar remeasurement purpose circumstance change company conclude long appropriate use official rate devaluation official rate occur result significant charge company future result operation company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment comprehensive income oci remain accumulated comprehensive income aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor record interest expense offset fair value change swap contract company terminate interest rate swap contract effectively convert company fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash cash flow contract report operating activity consolidate statement cash flow february connection company february debt offering note consolidated financial statement merck enter additional interest rate swap contract notional amount million effectively convert company note company note floatingrate instrument company investment portfolio include cash equivalent shortterm investment market value significantly affect change interest rate market value company medium longterm fixedrate investment modestly affect change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value table content merck investment debt change interest rate indicate percentage point increase interest rate december positively affect net aggregate market value instrument billion billion respectively percentage point decrease december negatively affect net aggregate market value billion billion respectively fair value merck debt determine pricing model reflect percentage point shift appropriate yield curve fair value merck investment determine combination pricing duration model critical accounting policy company consolidated financial statement prepare conformity gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement merger acquisition determine acquisition qualify business combination asset acquisition company make certain judgment include assessment input process output associate acquire set activity company determine acquisition consist input process apply input ability create output acquisition determine business combination business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition fair value intangible asset include acquire iprd determine utilize information available near merger acquisition date base expectation assumption deem reasonable management give considerable judgment involve determine fair value company typically obtain assistance thirdparty valuation specialist significant item amount allocate acquire iprd capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck separate determination useful life asset begin amortization certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probabilityweighte cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change record earning change input result significantly different fair value adjustment table content judgment determine estimate fair value assign asset acquire liability assume business combination asset life materially affect company result operation company determine transaction account acquisition business transaction account acquisition asset business combination goodwill record asset acquisition acquire iprd alternative future use charge expense acquisition date fair value identifiable intangible asset relate currently market product product right primarily determined income approach fair value estimate base asset discount project net cash flow company estimate market participant net cash flow consider historical project pricing margin expense level performance compete product applicable relevant industry therapeutic area growth driver factor current expect trend technology product life cycle time investment require develop product technology ability obtain market regulatory approval ability manufacture commercialize product extent time potential new product introduction company competitor life asset underlie patent net cash flow probabilityadjuste appropriate consider uncertainty associate underlie assumption risk profile net cash flow utilize valuation probabilityadjuste future net cash flow product discount present value utilize appropriate discount rate fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probabilityadjuste future net cash flow reflect different stage development product associate probability successful completion net cash flow discount present value appropriate discount rate revenue recognition revenue sale product recognize title risk loss pass customer typically time delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount customer collection account receivable expect excess year provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesaler contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid medicare benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler health maintenance organization pharmacy benefit manager customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision table content summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment balance december accrual chargeback reflect direct reduction account receivable accrual rebate current liability accrue balance relative provision include account receivable accrue current liability million billion respectively december million billion respectively december company maintain return policy allow pharmaceutical customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision pharmaceutical sale percentage net pharmaceutical sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return inventory produce preparation product launch company capitalize inventory produce preparation product launch sufficient support estimate initial market demand typically capitalization inventory begin relate product candidate phase clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory affect stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement inventory produce preparation product launch capitalize december million million respectively contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion table content overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust site investigation feasibility study relate cost assessment remedial technique complete extent potentially responsible party jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost past merck perform worldwide survey assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate definitive information available course investigation andor remedial effort site estimate refined accrual establish adjust accordingly estimate related accrual continue refine annually company believe compliance issue associate applicable environmental law regulation material adverse effect company expenditure remediation environmental liability million estimate million aggregate year management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year sharebase compensation company expense sharebase payment award employee include grant stock option requisite service period base grant date fair value award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option total pretax sharebase compensation expense million million million december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation cost unallocated expense table content pension postretirement benefit plan net periodic benefit cost pension postretirement benefit plan total million million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset decrease net periodic benefit cost pension postretirement benefit plan compare largely attributable change discount rate company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december discount rate company pension postretirement benefit plan range compare range december expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset reference information company develop forward look return expectation asset category weightedaverage expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return range range pension postretirement benefit plan october society actuary issue new retirement plan mortality assumption measure pension plan obligation company reflect impact new assumption measurement pension plan obligation december company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest nonus pension plan target investment portfolio vary base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net periodic benefit cost require funding obligation relate company pension postretirement benefit plan expect material precede hypothetical change discount rate expect rate return assumption impact company funding requirement net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci expect return pension plan base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize market relate value asset ratably fiveyear period net loss amount aoci excess certain threshold amortize net periodic benefit cost average remain service life employee table content restructuring cost restructuring cost record connection restructuring program design reduce cost structure increase efficiency enhance competitiveness result company estimate judgment future plan include future termination benefit exit cost incurred restructuring action place accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range connection action management assess recoverability longlive asset employ business certain instance asset life shorten base change expect useful life affect asset severance relate cost reflect restructuring cost assetrelate charge reflect material production cost market administrative expense research development expense depend nature asset impairment longlive asset company assess change economic regulatory legal condition make assumption estimate future cash flow evaluate value company property plant equipment goodwill intangible asset company periodically evaluate current fact circumstance indicate carry value longlive asset hold recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference asset fair value carry value quote market price available company estimate fair value discount value estimate future cash flow approach goodwill represent excess consideration transfer fair value net asset business purchase assign reporting unit company test goodwill impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying factor consider assessment include general macro economic condition condition specific industry market cost factor significant effect earning cash flow overall financial performance report unit sustained decline company share price additionally company evaluate extent fair value exceed carry value reporting unit date valuation perform company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible exclude iprd record fair value assign estimate useful life amortize primarily straightline basis estimate useful life event circumstance warrant review company assess recoverability future operation pretax undiscounte cash flow derive low appropriate asset grouping impairment recognize operating result extent carry value intangible asset exceed fair value determine base net present value estimate future cash flow iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform impairment testing purpose company combine separately record iprd intangible asset unit account base relevant fact circumstance generally company combine iprd intangible asset testing purpose operate single asset essentially inseparable fair value carrying impairment loss recognize company operating result table content judgment evaluate impairment longlive intangible materially affect company result operation impairment investment company review investment impairment base determination decline market value investment carrying value otherthantemporary company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthan temporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci taxis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual onetime item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company tax provision evaluate tax position recognition measurement tax position base management good judgment give fact circumstance information available reporting date company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement likely threshold meet period tax position take company subsequently recognize benefit tax position tax matter effectively settle statute limitation expire likely threshold meet subsequent period note consolidated financial statement tax regulation require item include tax return different time item reflect financial statement time difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability recently issue accounting standard financial accounting standard board issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement guidance effective annual interim period begin early adoption permit company currently assess impact adoption consolidate financial statement table content cautionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word anticipate expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forward look statement factor include inaccurate assumption broad variety risk uncertainty include know forwardlooke statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item risk factor annual report company discuss detail important risk factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie item quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation table content item financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income comprehensive income equity cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow consolidated statement income merck inc subsidiary year end december millions share amount sale cost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis tax income net income net income attributable noncontrolle interest net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder consolidate statement comprehensive income merck inc subsidiary year end december million net income attributable merck inc comprehensive income loss net taxis net unrealized gain loss derivative net reclassification net unrealized gain loss investment net reclassification benefit plan net loss gain prior service cost credit net amortization cumulative translation adjustment comprehensive income attributable merck inc accompany note integral consolidated financial statement table content consolidate balance sheet merck inc subsidiary december millions share amount asset current asset cash cash equivalent shortterm investment account receivable net allowance doubtful account exclude account receivable classified asset note inventory exclude inventory classified asset note defer income taxis current asset total current asset investment property plant equipment cost land building machinery equipment office furnishing construction progress accumulate depreciation goodwill intangible net asset liabilitie equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable total current liability longterm debt defer income taxis noncurrent liability merck inc stockholders equity common stock par value authorize share issue share paidin capital retain earning accumulate comprehensive loss treasury stock cost share share total merck inc stockholders equity noncontrolle interest total equity accompany note integral consolidated financial statement table content consolidate statement equity merck inc subsidiary year end december millions share amount accumulate non common paidin retain comprehensive treasury control stock capital earning loss stock interest total balance january net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive income net tax cash dividend declare common stock share supera joint venture formation treasury stock share purchase net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december net income attributable merck inc comprehensive loss net tax cash dividend declare common stock share treasury stock share purchase astrazeneca option exercise net income attributable noncontrolle interest distribution attributable noncontrolle interest sharebase compensation plan balance december accompanying note integral consolidated financial statement table content consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization intangible asset impairment charge gain divestiture merck consumer care gain astrazeneca option exercise loss extinguishment debt equity income affiliate dividend distribution equity method affiliate defer income taxis sharebase compensation net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability net cash provide operating activity cash flow invest activity capital expenditure purchase security investment proceed sale security investment divestiture consumer care business net cash divest disposition business net cash divest proceed astrazeneca option exercise acquisition idenix pharmaceuticals inc net cash acquire acquisition business net cash acquire acquisition bayer collaboration right cash inflow net investment hedge net cash investing activity cash flow financing activity net change shortterm borrowing payment debt proceed issuance debt purchase treasury stock dividend pay stockholder dividend pay proceed exercise stock option net cash financing activity effect exchange rate change cash cash equivalent net decrease increase cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement table content note consolidated financial statement merck inc subsidiarie million share amount nature operation merck inc merck company global health care company deliver innovative health solution prescription medicine vaccine biologic therapie animal health product market directly joint venture company operation principally manage product basis comprise operate segment pharmaceutical animal health alliance segment reportable segment pharmaceutical segment pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer october company divest consumer care segment note develop manufacture market overthecounter foot care sun care product summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain intercompany balance transaction eliminate control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside shareholder interest show noncontrolle interest equity investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis merger acquisition business combination acquisition method accounting require asset acquire liability assume record date merger acquisition respective fair value limited exception asset acquire liability assume business combination arise contingency recognize fair value fair value reasonably estimate acquisition date fair value asset acquire liability assume arise contingency determine asset liability recognize probable reasonably estimable criterion meet asset liability recognize fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date accordingly company require value asset fair value measure reflect company intend use asset excess purchase price consideration transfer estimate fair value net asset acquire record goodwill transaction cost cost restructure acquire company expense incur operating result acquire business reflect company consolidate financial statement date merger acquisition company determine asset acquire meet definition business acquisition method accounting transaction account acquisition asset business combination goodwill record foreign currency translation net asset international subsidiary local currency determine functional currency translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate record foreign currency translation account include accumulate comprehensive income loss aoci table content reflect separate component equity subsidiary operate highly inflationary economy subsidiarie dollar determine functional currency nonmonetary foreign currency asset liability translate historical rate monetary asset liability translate current rate dollar effect rate change include income expense net cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory inventory value low cost market cost substantial majority domestic pharmaceutical vaccine inventory determine lastin firstout lifo method financial report tax purpose cost inventory determine firstout fifo method inventory consist currently market product certain inventory produce preparation product launch consider high probability regulatory approval evaluate recoverability inventory produce preparation product launch company consider likelihood revenue obtain future sale relate inventory status product regulatory approval process investment investment marketable debt equity security classify availableforsale report fair value fair value company investment determine quote market price active market identical asset liability quote price similar asset liability input observable corroborate observable market datum substantially term asset liability change fair value consider temporary report net tax comprehensive income oci decline fair value equity security consider thantemporary impairment loss charge income expense net company consider available evidence evaluate potential impairment investment include duration extent fair value cost equity security company ability intent hold investment debt security otherthantemporary impairment occur company expect recover entire amortize cost basis debt security company intend sell impair debt security likely require sell debt security recovery amortize cost basis otherthantemporary impairment recognize earning record income expense net limited portion attribute credit loss remain portion otherthantemporary impairment relate factor recognize oci realize gain loss debt equity security include income expense net revenue recognition revenue sale product recognize title risk loss pass customer typically delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesaler know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale addition revenue record net time value money discount collection account receivable expect excess year accrual chargeback reflect direct reduction account receivable accrual rebate record current liability accrue balance relative provision chargeback rebate include account receivable accrue current liability million billion respectively december million billion respectively december company recognize revenue sale vaccine federal government placement vaccine stockpile accordance security exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate tax method estimate useful life primarily range year building year machinery equipment office furnishing depreciation expense billion billion billion table content advertising promotion cost advertising promotion cost expense incur company record advertising promotion expense billion billion billion respectively software capitalization company capitalize certain cost incur connection obtain develop internaluse software include external direct cost material service payroll cost employee directly involve software development capitalize software cost include property plant equipment amortize begin software project substantially complete asset ready intend use capitalize software cost associate project amortize year include company ongoing multiyear implementation enterprisewide resource planning system million million net accumulate amortization december respectively capitalize software cost amortize period range year cost incur preliminary project stage postimplementation stage maintenance training cost expense incur goodwill goodwill represent excess consideration transfer fair value net asset business purchase goodwill assign reporting unit evaluate impairment annual basis frequently impairment indicator exist assess qualitative factor determine likely fair value report unit carrying company conclude likely fair value report unit carrying quantitative fair value test perform acquire intangible acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life range year note company periodically evaluate current fact circumstance indicate carry value acquire intangible recoverable circumstance determine exist estimate undiscounted future cash flow asset appropriate asset grouping compare carry value determine impairment exist asset determine impair loss measure base difference carry value intangible asset fair value determine base net present value estimate future cash flow acquire inprocess research development acquire inprocess research development iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize account indefinitelive intangible asset subject impairment testing completion abandonment project successful completion project merck determination useful life intangible asset generally determine period substantial majority cash flow expect generate begin amortization company test iprd impairment annually frequently impairment indicator exist assess qualitative factor determine likely fair value iprd intangible asset carrying company conclude likely fair value carrying quantitative test compare fair value iprd intangible asset carrying value perform fair value carrying impairment loss recognize operating result contingent consideration certain company business acquisition involve potential future payment consideration contingent achievement performance milestone include product development milestone royalty payment future product sale fair value contingent consideration liability determine acquisition date unobservable input input include estimate time project cash flow probability success achievement contingent event riskadjuste discount rate present value probability weight cash flow subsequent acquisition date report period contingent consideration liability remeasure current fair value change record earning change input result significantly different fair value adjustment research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize table content amortize shorter remaining license product patent life amount collaborative partner relate development activity generally reflect reduction research development expense specific milestone achieve nonrefundable advance payment good service future research development activity expense activity perform good receive payment research development expense include restructure cost iprd impairment charge period addition research development expense include charge increase fair value liability contingent consideration sharebase compensation company expense sharebased payment employee requisite service period base grantdate fair value award restructuring cost company record liability cost associate exit disposal activity period liability incur accordance exist benefit arrangement employee termination cost accrue restructuring action probable estimable accrue cost company recognize range cost good estimate range range well estimate company recognize minimum range cost onetime termination benefit employee require render service termination order receive benefit recognize ratably future service period contingency legal defense cost company record accrual contingency legal defense cost expect incur connection loss contingency probable liability incur reasonably estimate taxis income defer taxis recognize future tax effect temporary difference financial income tax reporting base enact tax law rate company evaluate tax position determine benefit tax position likely sustain audit base technical merit tax position tax position likely sustain audit company recognize large benefit greater likely realize ultimate settlement financial statement tax position likely sustain audit company recognize portion benefit financial statement company recognize interest penalty associate uncertain tax position component taxis income consolidate statement income use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate accounting amount record connection merger acquisition include initial fair value determination asset liability primarily iprd intangible asset subsequent fair value measurement additionally estimate determine item provision sale discount return depreciable amortizable live recoverability inventory include produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption restructure cost impairment longlive asset include intangible asset goodwill investment tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently issue accounting standard financial accounting standard board issue amend accounting guidance revenue recognition apply contract customer objective new guidance improve comparability revenue recognition practice entity provide useful information user financial statement improve disclosure requirement guidance effective annual interim period begin early adoption permit company currently assess impact adoption consolidate financial statement table content restructure restructure program company announce global restructure program restructuring program global initiative sharpen commercial research development focus program company expect reduce total workforce approximately position workforce reduction primarily come elimination position sale administrative headquarters organization research development company reduce global real estate footprint continue improve efficiency manufacture supply network company continue hire employee strategic growth area business necessary company record total pretax cost billion related restructuring program inception restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position action restructure program expect substantially complete end cumulative pretax cost estimate approximately billion company estimate approximately twothird cumulative pretax cost result cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divest merger restructuring program subsequent merck scheringplough corporation scheringplough merger merger company commence action global restructuring program merger restructuring program design streamline cost structure combine company action program initiate action program primarily reflect elimination position sale administrative headquarters organization sale closure certain manufacturing research development site consolidation office facility october company sell active pharmaceutical ingredient api manufacturing business include related manufacturing facility netherland aspen holding aspen plan manufacturing facility rationalization merger restructuring program conjunction sale party enter strategic longterm supply agreement aspen supply api company approximately employee support api business transfer merck aspen connection sale aspen acquire certain brand product merck transfer aspen effective december consideration transaction include cash million note receivable present value million time disposition note receivable consist million note present value million million note present value million payable year begin december cash portion consideration company receive million fourth quarter remain million receive company january december record receivable deferred income taxis current asset consolidate balance sheet conjunction transaction company transfer inventory million property plant equipment million cash million aspen reduce goodwill million intangible asset million asset million record million transactionrelated liability transaction result loss million record restructuring cost table content company record total pretax cost million billion million related restructuring program inception merger restructuring program december merck record total pretax accumulate cost approximately billion eliminate approximately position comprise employee separation elimination contractor vacant position approximately position elimination remain pende program december include remain action restructure program report merger restructuring program discuss nonmanufacture related restructuring action merger restructuring program substantially complete end remain action program primarily relate ongoing manufacturing facility rationalization expect substantially complete company expect estimate total cumulative pretax cost program approximately billion company estimate approximately twothird cumulative pretax cost relate cash outlay primarily relate employee separation expense approximately onethird cumulative pretax cost noncash relate primarily accelerate depreciation facility close divested restructure program merck announce global restructure program restructuring program reduce cost structure increase efficiency enhance competitiveness pretax cost million million record respectively relate restructuring program effective july remain activity restructuring program account merger restructure program segment report restructuring charge unallocated expense table content follow table summarize charge related restructuring program activity type cost separation accelerate year end december costs depreciation total restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost year end december restructuring program material production marketing administrative research development restructuring cost merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost year end december merger restructuring program material production marketing administrative research development restructuring cost restructure program material production marketing administrative restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate position eliminate restructure program approximately position eliminate merger restructuring program approximately position elimination comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate manufacture research administrative facility equipment sell closed program accelerate depreciation cost represent difference depreciation expense recognize revise useful life site base anticipated date table content site close divest depreciation expense determine utilize useful life prior restructure action site continue operate respective closure date future undiscounte cash flow sufficient recover respective book value merck require accelerate depreciation site asset record impairment charge anticipate site closure date particularly related manufacturing location continue adjust reflect change result regulatory factor activity include million million million respectively asset abandonment shutdown relate cost additionally activity include certain employeerelate cost associate pension postretirement benefit plan note share base compensation activity reflect net pretax loss gain result sale facility relate asset million million primarily reflect loss transaction aspen discuss million adjustment previously record amount material period follow table summarize charge spend relate restructuring activity program separation accelerate cost depreciation total restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december merger restructuring program restructuring reserve january expense payment receipt net noncash activity restructuring reserve december expense payment receipt net noncash activity restructure reserve december cash outlay associate restructuring program expect substantially complete end nonmanufacture cash outlay associate merger restructuring program substantially complete end remain cash outlay expect substantially complete end acquisition divestiture research collaboration license agreement company continue strategy establish external alliance complement substantial internal research capability include research collaboration license preclinical clinical compound drive near longterm growth company supplement internal research license external alliance strategy focus entire spectrum collaboration early research latestage compound access new technology arrangement include upfront payment expense reimbursement payment party milestone royalty profit share payment contingent occurrence certain future event link success asset development company review pipeline examine candidate provide value outlicense portfolio assessment process divest certain product table content december merck cubist pharmaceuticals inc cubist announce definitive agreement merck acquire cubist total purchase price approximately billion cubist leader development new therapy treat potentially lifethreatening infection cause broad range increasingly drugresistant bacteria transaction close january accordingly result operation acquire business include company result operation begin date december merck acquire oncoethix privately hold biotechnology company specialize oncology drug development total purchase consideration transaction million include upfront cash payment million future additional milestone payment million contingent certain clinical regulatory milestone achieve company determine fair value million acquisition date transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption merck recognize intangible asset iprd million relate otx investigational novel oral bet bromodomain inhibitor currently phase study treatment hematological malignancy advance solid tumor liability contingent consideration million net asset liability million fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate fair value contingent consideration determine utilize probability weight estimate cash flow stream adjust expect timing payment utilize discount rate transaction close december accordingly result operation acquire business include company result operation begin date pro forma financial information include oncoethixs historical financial result significant compare company financial result october company complete sale merck consumer care mcc business bayer bayer billion billion net cash divest customary closing adjustment certain contingent amount hold payable manufacturing site transfer canada regulatory approval korea term agreement bayer acquire merck exist overthecounter business include global trademark prescription right claritin afrin company recognize pretax gain sale mcc billion october company enter worldwide clinical development collaboration bayer market develop portfolio soluble guanylate cyclase sgc modulator include bayers adempas riociguat member novel class compound adempas approve treat pulmonary arterial hypertension pah drug treatment approve patient chronic thromboembolic pulmonary hypertension cteph adempas currently market united states europe pah cteph japan cteph company equally share cost profit collaboration implement joint development commercialization strategy collaboration include clinical development bayer vericiguat currently phase trial worsen heart failure optin right earlystage sgc compound development bayer merck turn available earlystage sgc compound similar term return broad collaboration right merck upfront payment bayer billion potential additional milestone payment achievement agreedupon sale goal adempas bayer continue lead commercialization america merck lead commercialization rest world vericiguat potential optin product bayer lead rest world merck lead america product candidate include agreement company share development cost profit sale right copromote territory lead company determine merck payment access bayer compound constitute acquisition asset billion consideration pay merck million fair value relate currently market product adempas capitalize intangible asset subject amortization estimate useful life year remain million fair value relate vericiguat compound currently clinical development expense research development expense fair value adempas vericiguat determine income approach fair value estimate base probability adjust future net cash flow vericiguat stage development project associate probability table content successful completion net cash flow discount present value discount rate adempas vericiguat future sale base milestone accrue probable reasonably estimable company bayer right terminate agreement cause productbyproduct basis product develop commercialize agreement adempas bayer termination right event party material uncured breach relate product september merck sun pharmaceutical industries ltd sun pharma enter exclusive worldwide licensing agreement merck investigational therapeutic antibody candidate tildrakizumab treatment chronic plaque psoriasis skin ailment term agreement sun pharma acquire worldwide right tildrakizumab use human indication merck exchange upfront payment million merck continue clinical development regulatory activity fund sun pharma product approval sun pharma responsible regulatory activity include subsequent submission pharmacovigilance post approval study manufacturing commercialization approve product merck eligible receive future payment associate regulatory include product approval sale milestone tiere royalty range midsingle digit teen percentage rate sale merck record loss million transaction include income expense net august merck complete acquisition idenix pharmaceuticals inc idenix approximately billion cash billion net cash acquire idenix biopharmaceutical company engage discovery development medicine treatment human viral disease primary focus development nextgeneration oral antiviral therapeutic treat hepatitis virus hcv infection transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value acquisition date determination fair value require management significant estimate assumption merck recognize intangible asset iprd billion related idx net defer tax liability million net asset liability approximately million nucleotide prodrug phase clinical development evaluate potential inclusion development oral pangenotypic fixeddose combination regimen excess consideration transfer fair value net asset acquire billion record goodwill allocate pharmaceutical segment deductible tax purpose fair value identifiable intangible asset relate iprd determine income approach fair value estimate base asset probability adjust future net cash flow reflect stage development project associate probability successful completion net cash flow discount present value discount rate transaction close august accordingly result operation acquire business include company result operation begin date pro forma financial information include idenixs historical financial result significant compare company financial result merck enter agreement sell certain ophthalmic product santen pharmaceutical ltd santen japan markets europe asia pacific ophthalmic product include agreement cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution cosopt dorzolamide hydrochloridetimolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution sterile ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution preservativefree timoptic timolol maleate ophthalmic solution timoptic timolol maleate preservative free ophthalmic solution unit dose dispenser timoptic timolol maleate ophthalmic gel forming solution saflutan tafluprost taptiqom tafluprosttimolol maleate ophthalmic solution development agreement provide santen upfront payment additional payment base define sale milestone santen purchase supply ophthalmology product cover agreement fiveyear period closing transaction market july company receive million upfront payment santen net certain adjustment additional million close remain market october merck recognize gain million transaction include income expense net march merck divest sirna therapeutics inc sirna subsidiary alnylam pharmaceuticals inc alnylam consideration million share alnylam common stock merck eligible receive future payment associate achievement certain regulatory commercial milestone royaltie future sale term agreement merck receive alnylam share quarter value million time close remain share second quarter table content value million time share receive merck record gain million relate transaction include income expense net excess merck tax basis investment sirna value receive result approximate million tax benefit record january merck sell marketing right saphris asenapine antipsychotic indicate treatment schizophrenia bipolar disorder adult forest laboratories inc forest term agreement forest upfront payment million record sale additional payment merck base define sale milestone addition transaction merck agree supply product forest subsequently acquire actavis plc patent expiry september merck astrazeneca announce worldwide outlicense agreement merck oral small molecule inhibitor wee kinase evaluate clinical study combination standardofcare therapie treatment patient certain type ovarian cancer term agreement astrazeneca pay merck million upfront fee company record revenue addition merck eligible receive future payment tie development regulatory milestone plus salesrelated payment tiere royalty astrazeneca responsible future clinical development manufacturing marketing april merck pfizer inc pfizer announce worldwide japan collaboration agreement development commercialization pfizer ertugliflozin investigational oral sodium glucose cotransporter sglt inhibitor evaluate treatment type diabetes company initiate phase clinical trial ertugliflozin pfizer term agreement merck pfizer collaborate clinical development commercialization ertugliflozin ertugliflozincontaine fixeddose combination metformin januvia sitagliptin tablets merck continue retain right exist portfolio sitagliptincontaine product end merck record research development expense million upfront milestone payment pfizer pfizer eligible additional payment associate achievement prespecifie future clinical regulatory commercial milestone company share potential revenue certain cost merck pfizer party certain manufacturing supply obligation company pfizer right terminate agreement material uncured breach insolvency party event safety issue pfizer right terminate agreement month notice time follow anniversary commercial sale collaboration product assign right ertugliflozin merck termination agreement depend circumstance party vary right obligation respect continued development commercialization ertugliflozin certain payment obligation february merck supera farma laboratorio supera brazilian pharmaceutical company coowne cristlia eurofarma establish joint venture market distribute sell portfolio pharmaceutical brand generic product merck cristlia eurofarma brazil merck own joint venture cristlia eurofarma collectively transaction account acquisition business accordingly asset acquire liability assume recorded respective fair value result merck recognize intangible asset currently market product million iprd million goodwill million defer tax liability million company record increase noncontrolle interest paidin capital amount million million respectively transaction close february accordingly result operation acquire business include company result operation begin date result change cash flow assumption certain compound company record million asset impairment charge relate iprd record supera transaction change cash flow assumption compound certain currently market product result writeoff goodwill balance relate joint venture supera million exist exchange rate company previously record million impairment charge fourth quarter relate iprd record supera transaction result change cash flow assumption certain compound remicadesimponi subsidiary scheringplough enter licensing agreement centocor ortho biotech inc centocor johnson johnson company market remicade prescribe treatment inflammatory disease scheringplough subsidiary exercise option contract centocor table content license right develop commercialize simponi fully human monoclonal antibody company exclusive marketing right product europe russia turkey december scheringplough centocor revise distribution agreement development commercialization distribution remicade simponi extend company right exclusively market remicade match duration company exclusive marketing right simponi addition scheringplough centocor agree share certain development cost relate simponis auto injector delivery system october european commission approve simponi treatment rheumatoid arthritis immune system disorder presentation novel autoinjector prefille syringe result company marketing right product extend year commercial sale simponi european union follow receipt pricing reimbursement approval remicade lose market exclusivity major european market february profit derive merck exclusive distribution product equally divide merck financial instrument derivative instrument hedging activity company manage impact foreign exchange rate movement interest rate movement earning cash flow fair value asset liability operational mean use financial instrument include derivative instrument significant portion company revenue earning foreign affiliate expose change foreign exchange rate objective account relate companys foreign currency risk management program interest rate risk management activity discuss foreign currency risk management company establish revenue hedge balance sheet risk management net investment hedging program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange rate decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company hedge portion forecast foreign currency denominate thirdparty intercompany distributor entity sale expect occur planning cycle typically year future company layer hedge time increase portion thirdparty intercompany distributor entity sale hedge get close expect date forecast foreign currency denominate sale portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged currency risk manner company manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow offset decline expect future dollar equivalent cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow connection company revenue hedging program purchase collar option strategy utilize purchase collar option strategy company write local currency option purchase local currency option compare purchase option strategy purchase collar strategy reduce upfront cost associate purchasing put collection premium write option dollar weaken relative currency hedge anticipate sale purchase option value collar strategy reduce zero company benefit increase dollar equivalent value anticipate foreign currency cash flow benefit cap strike level write dollar strengthen relative currency hedge anticipate sale write option value collar table content strategy reduce zero change purchase cash flow collar strategy offset decline expect future dollar equivalent cash flow hedge foreign currency sale company utilize forward contract revenue hedging program dollar strengthen relative currency hedge anticipate sale increase fair value forward contract offset decrease expect future dollar cash flow hedge foreign currency sale conversely dollar weaken decrease fair value forward contract offset increase value anticipate foreign currency cash flow fair value derivative contract record asset gain position liability loss position consolidate balance sheet change fair value derivative contract record period current earning oci depend derivative designate hedge transaction type hedge transaction derivative designate cash flow hedge effective portion unrealize gain loss contract record aoci reclassify sale hedge anticipate revenue recognize hedge relationship highly effective hedge ineffectiveness minimis derivative designate cash flow hedge serve economic hedge forecast sale unrealize gain loss record sale period cash flow designate nondesignate contract report operating activity consolidate statement cash flow company enter derivative trade speculative purpose primary objective balance sheet risk management program mitigate exposure foreign currency denominate net monetary asset foreign subsidiary dollar functional currency effect volatility foreign exchange instance merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange monetary asset merck routinely enter contract offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract partially offset effect exchange exposure deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level cash flow contract report operating activity consolidate statement cash flow monetary asset liability denominate currency functional currency give subsidiary remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward exchange contract hedge net investment foreign operation movement exchange rate forward contract designate hedge net investment foreign operation company hedge portion net investment certain foreign operation measure ineffectiveness base change spot foreign exchange rate effective portion unrealize gain loss contract record foreign currency translation adjustment oci remain aoci sale complete substantially complete liquidation subsidiary cash flow contract report investing activity consolidate statement cash flow foreign exchange risk manage use foreign currency debt company senior unsecured eurodenominate note designate effective economic hedge net investment foreign operation accordingly foreign currency transaction gain loss spot rate fluctuation eurodenominate debt instrument include foreign currency translation adjustment oci include cumulative translation adjustment pretax gain million pretax loss million million eurodenominate note table content interest rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note detailed table number interest rate total swap notional debt instrument par value debt swap hold note note note note note interest rate swap contract designate hedge fair value change note attributable change benchmark london interbank offer rate libor swap rate fair value change note attributable change libor record interest expense offset fair value change swap contract company terminate interest rate swap contract effectively convert company fixedrate note floatingrate instrument interest rate swap contract designate hedge fair value change note attributable change benchmark libor swap rate result swap termination company receive million cash cash flow contract report operating activity consolidate statement cash flow february connection company february debt offering note merck enter additional interest rate swap contract notional amount million effectively convert company note company note float rate instrument table content present table fair value derivative gross basis segregate derivative designate hedge instrument designate hedge instrument december fair value fair value derivative derivative dollar dollar balance sheet caption asset liability notional asset liability notional derivative designate hedge instrument interest rate swap contract non current asset interest rate swap contract non current noncurrent liability foreign exchange contract current defer income taxis current asset foreign exchange contract non current asset foreign exchange contract current accrue current liability derivative designate hedge instrument foreign exchange contract current defer income taxis current asset foreign exchange contract current accrue current liability note company record derivative gross basis consolidated balance sheet company master netting agreement financial institution counterpartie concentration credit risk follow table provide information company derivative position subject master netting arrangement present net basis allow right offset counterparty cash collateral exchange master agreement relate credit support annexe december asset liability asset liability gross amount recognize consolidated balance sheet gross subject offset master netting arrangement offset consolidated balance sheet cash collateral receive post net amount table content table provide information location pretax gain loss amount derivative designate fair value hedge relationship designate foreign currency cash flow hedging relationship iii designate foreign currency net investment hedge relationship designate hedge relationship year end december derivative designate fair value hedge relationship interest rate swap contract gain loss recognize income expense net derivative loss gain recognize income expense net hedge item derivative designate foreign currency cash flow hedging relationship foreign exchange contract gain loss reclassify aoci sale gain loss recognize oci derivative derivative designate foreign currency net investment hedging relationship foreign exchange contract gain recognize income expense net derivative gain recognize oci derivative derivative designate hedge relationship foreign exchange contract gain loss recognize income expense net derivative loss recognize sale million million ineffectiveness hedge respectively ineffectiveness hedge represent exclude hedge effectiveness testing derivative contract mitigate change value remeasure foreign currency denominate monetary asset liability attributable change foreign currency exchange rate december company estimate million pretax net unrealize gain derivative mature month hedge foreign currency denominate sale period reclassify aoci sale ultimately reclassify sale differ foreign exchange rate change realize gain loss ultimately determine actual exchange rate maturity table content investment debt equity security information availableforsale investment december follow gross unrealized gross unrealize fair amortize fair amortize value cost gain loss value cost gain loss corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security availableforsale debt security include shortterm investment total billion december remain debt security billion mature year december debt security pledge collateral fair value measurement fair value define exchange price received asset pay transfer liability exit price principal advantageous market asset liability orderly transaction market participant measurement date company use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset liability value determine pricing model discount cash flow methodology similar technique significant unobservable input asset liabilitie determination fair value require significant judgment estimation input measure financial asset liability fall level describe categorization base low level input significant fair value measurement instrument table content financial asset liability measure fair value recur basis financial asset liability measure fair value recur basis december summarize fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset investment corporate note bond commercial paper government agency security assetbacke security mortgagebacke security foreign government bond equity security asset security hold employee compensation derivative asset purchase currency option forward exchange contract interest rate swap total asset liability liabilitie contingent consideration derivative liability forward exchange contract write currency option interest rate swap total liability primarily assetbacke security highlyrate standard poor rate aaa moodys investor service rating aaa secure primarily credit card auto loan home equity receivables weightedaverage live primarily year mortgagebacked security represent aaarate security issue unconditionally guarantee payment principal interest government agency fair value determination derivative include impact credit risk counterpartie derivative companys credit risk effect significant transfer level level december cash cash equivalent billion include billion cash equivalent consider level fair value hierarchy table content contingent consideration summarize information change liabilitie contingent consideration follow fair value january change fair value record research development expense addition fair value december fair value liability contingent consideration relate acquisition occur increase million result progression program preclinical phase increase result high fair value future regulatory milestone royalty payment increase probability success program give progression phase addition company recognize liability million contingent consideration relate acquisition oncoethix note fair value measurement company financial instrument cash cash equivalent receivables payable reflect balance sheet carrying value approximate fair value shortterm nature estimate fair value loan payable longterm debt include current portion december billion compare carry value billion december billion compare carry value billion fair value estimate recent observable market price consider level fair value hierarchy concentration credit risk ongoing basis company monitor concentration credit risk associate corporate government issuer security financial institution conduct business credit exposure limit establish limit concentration single issuer institution cash investment place instrument meet high credit quality standard specify company investment policy guideline majority company account receivable arise product sale united states europe primarily drug wholesaler retailer hospital government agency manage health care provider pharmacy benefit manager company monitor financial performance creditworthiness customer properly assess respond change credit profile company continue monitor economic condition include volatility associate international sovereign economy associate impact financial market business take consideration global economic condition ongoing sovereign debt issue certain european country company continue monitor credit economic condition greece italy spain portugal member economic condition inherent variability time cash receipt result continue result increase average length time take collect account receivable outstanding time value money discount record customer collection account receivable expect excess year december asset include million million respectively account receivable expect collect year company expect writeoff adjustment account receivable material adverse effect financial position liquidity result operation december company account receivable greece italy spain portugal total approximately million hospital public sector receivables approximately million aggregate approximately relate greece italy spain portugal respectively december company total net account receivable outstanding year approximately million approximately relate account receivable greece italy spain portugal comprise hospital public sector receivables table content company complete nonrecourse factoring spain approximately million italy approximately million hospital public sector receivables company complete nonrecourse factoring approximately million hospital public sector receivables spain company collect approximately million account receivable connection spanish government debt stabilizationstimulus plan addition company complete nonrecourse factoring approximately million hospital public sector account receivable italy additionally company continue expand emerge market payment term market tend long result increase account receivable balance certain market company customer large account receivable balance amerisourcebergen corporation cardinal health inc mckesson corporation aah pharmaceuticals ltd zuellig pharma ltd asia pacific represent aggregate approximately total account receivable december company monitor creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale derivative financial instrument execute international swap derivative association master agreement master agreement company financial institution counterpartie include credit support annexe annexe contain provision require collateral exchange depend value derivative asset liability company credit rating credit rating counterparty december company receive cash collateral billion million respectively counterpartie obligation return collateral record accrue current liability company advanced cash collateral counterpartie december inventory inventory december consist finished good raw material work process supply total approximate current cost increase lifo cost recognize inventory asset inventory value lifo method comprise approximately billion billion inventory december respectively amount recognize asset comprise entirely raw material work process inventory december amount include billion billion respectively inventory expect sell year addition amount include million million december respectively inventory produce preparation product launch table content goodwill intangible follow table summarize goodwill activity segment pharmaceutical total balance january acquisition divestiture balance december acquisition divestiture impairment balance december include cumulative translation adjustment goodwill balance certain adjustment accumulate goodwill impairment loss december million addition goodwill pharmaceutical segment primarily result acquisition idenix reduction result sale mcc divestiture certain ophthalmic product international market note reduction goodwill segment result termination company relationship astrazeneca azlp note divestiture mcc quarter company record impairment charge goodwill relate supera joint venture note company perform recent annual impairment test october conclude goodwill impair addition pharmaceutical segment goodwill result formation supera joint venture note reduction result divestiture company api manufacturing business relate brand product note july company acquire remain share physician interactive provider online mobile clinical resource solution health care professional merck exist ownership interest million november merck acquire health management resource corporation leader medical weight management million transaction collectively result addition approximately million goodwill include segment pro forma financial information include transaction historical financial result significant compare company financial result intangible december consist gross gross carrying accumulate carry accumulate amortization net amortization net product product right inprocess research development tradename acquire intangible include product product right tradename patent record fair value assign estimate useful life amortize primarily straightline basis estimate useful life company significant acquire intangible relate market product include product product right december include zetia billion vytorin billion nasonex table content million nuvare million implanonnexplanon million company recognize intangible asset related adempas result formation collaboration bayer note carry value million december reflect table billion intangible asset divest connection sale mcc note company record impairment charge relate market product billion million respectively material production cost record million relate pegintron million relate victrelis million relate rebetol product market company treatment chronic hcv sale product adversely affect loss market share patient treatment delay market anticipate availability new therapeutic option trend accelerate rapidly previously anticipate company addition development competitive hcv treatment market lead market share loss great company predict factor cause change cash flow projection pegintron victrelis rebetol indicate intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate pegintron victrelis rebetol compare related carry value result impairment charge note record million result low cash flow projection saphrissycrest reduce expectation international markets united states revision cash flow indicate saphrissycr intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption consider different scenario determine good estimate fair value intangible asset relate saphrissycrest compare related carrying value result impairment charge note remain million impairment charge result low cash flow projection rebetol reduce expectation japan europe revision cash flow indicate rebetol intangible asset value recoverable undiscounted cash flow basis company utilize market participant assumption determine good estimate fair value intangible asset relate rebetol compare related carrying value result impairment charge note iprd company acquire business combination represent fair value assign incomplete research project time acquisition reach technological feasibility amount capitalize iprd account indefinitelive intangible asset subject impairment testing completion abandonment project company record iprd billion related acquisition idenix note successful completion project company separate determination useful life asset begin amortization million million million respectively iprd reclassify product product right receipt marketing approval major market company record million iprd impairment charge research development expense primarily result change cash flow assumption certain compound obtain connection supera joint venture discontinuation certain animal health program company record million iprd impairment charge million relate writeoff intangible asset associate preladenant result discontinuation clinical development program compound addition company record impairment charge result change cash flow assumption certain compound pipeline program previously deprioritize subsequently deem alternative use period company record million iprd impairment charge primarily pipeline program previously deprioritize subsequently deem alternative use period iprd project remain development subject inherent risk uncertaintie drug development possible company able successfully develop complete iprd program profitably commercialize underlie product candidate company recognize additional noncash impairment charge future relate market product pipeline program charge material aggregate amortization expense primarily record material production cost billion billion billion estimate aggregate amortization expense table content year follow billion billion billion billion million joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow year end december astrazeneca note july company long record equity income azlp include result sanofi pasteur msd astrazeneca merck enter agreement astra astra develop market astra product royaltybeare license merck total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states merck astra complete restructure ownership operation joint venture merck acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc exclusive distributor product kbi retain right merck earn revenue base sale kbi product revenue million million million respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement preferential return represent merck share undistribute azlp gaap earning variable return relate companys limited partner interest june astrazeneca exercise option purchase merck interest kbi million cash million reflect estimate fair value merck interest nexium prilosec portion exercise price subject trueup base actual sale closing june defer recognize time income expense net contingency eliminate sale occur million defer revenue recognize income expense net remain exercise price million primarily represent multiple time merck average annual profit allocation partnership year prior exercise merck recognize million gain income expense net result astrazenecas option exercise company remain interest azlp redeem accordingly company recognize noncash gain approximately million income expense net result retirement billion kbi prefer stock note elimination company billion investment azlp million reduction goodwill transaction result net tax benefit million primarily reflect reversal defer taxis azlp investment balance result astrazeneca exercise option july company long record equity income azlp supply sale azlp terminate table content summarize financial information azlp follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability include result june termination date merck partnership return azlp generally contractually determine note base percentage income azlp respect mercks limited partnership interest sanofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale billion billion billion investment affiliate account equity method include joint venture total million december billion december amount report asset amount joint venture include defer income taxis current asset million december million december summarize information affiliate exclude azlp disclose separately follow year end december sale material production cost expense net income taxis december current asset noncurrent asset current liability noncurrent liability loan payable longterm debt commitment loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder loan payable december include billion note billion commercial paper million shortterm foreign borrowing million longdate note subject repayment option holder weightedaverage interest rate commercial paper borrowing december respectively table content longterm debt december consist note note note eurodenominate note eurodenominate note note note floatingrate borrow note note note note note eurodenominate note note floatingrate borrow note note note debenture debenture debenture note note note present table include million million december respectively borrowing variable rate average include foreign borrowing million million december respectively vary rate respectively exception debenture note list table redeemable merck option time vary redemption price october company issue eurodenominate senior unsecured note consist billion principal note billion principal note million principal note interest note payable annually note series redeemable time company option vary redemption price net proceed offer billion repay debt validly tender connection tender offer launch company certain outstanding note debenture company pay billion aggregate consideration applicable purchase price accrue interest redeem billion principal debt addition november merck redeem billion note billion note company record pretax loss million connection transaction february merck issue billion aggregate principal senior unsecured note consist million principal float rate note million principal float rate note billion principal note billion aggregate principal note billion aggregate principal note billion aggregate principal note company substantial portion net proceed offer repay table content commercial paper issue substantially finance company acquisition cubist remain net proceed general corporate purpose include limitation repurchase company common stock repayment outstanding commercial paper borrowing upcoming debt maturity december company enter bridge loan agreement certain bank pursuant company ability borrow billion purpose obtain shortterm financing acquisition cubist company borrow fund bridge loan issue billion senior unsecured note discuss terminate bridge loan february effective november company execute unconditional guarantee exist debt subsidiary merck sharp dohme corp msd msd execute unconditional guarantee exist debt company exclude commercial paper include payment principal interest guarantee extend debt issue subsequent date certain company borrowing require merck comply financial covenant include requirement total debt capitalization ratio define applicable agreement exceed december company compliance covenant aggregate maturity longterm debt year follow billion billion million billion billion amount reflect debt maturity relate company february debt issuance describe august company terminate exist credit facility enter new billion fiveyear credit facility mature august facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility rental expense operating lease net sublease income million million million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation certain additional matter include environmental matter vioxx litigation define separate assessment provide note opinion company unlikely resolution matter material company financial position result operation cash flow give nature litigation discuss include vioxx litigation complexity involve matter company unable reasonably estimate possible loss range possible loss matter company know factor claim survive dispositive motion practice extent claim include size potential class particularly damage specify indeterminate iii discovery process affect litigation settlement posture party litigation factor material effect litigation company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august table content vioxx litigation product liability lawsuit previously disclose merck defendant approximately active federal state lawsuit vioxx product liability lawsuit allege personal injury result use vioxx case coordinate multidistrict litigation district court eastern district louisiana vioxx mdl judge eldon fallon previously disclose merck defendant approximately putative class action lawsuit allege economic injury result purchase vioxx case vioxx mdl merck reach resolution approve judge fallon class action vioxx mdl settlement merck pay million pay properly document claim submit class member approve attorney fee expense approve settlement notice cost certain administrative expense court enter order approve settlement january merck defendant lawsuit bring state attorney general state alaska montana utah action pende vioxx mdl proceeding october judicial panel multidistrict litigation jpml issue order remand action original federal court action allege merck misrepresented safety vioxx seek recovery expenditure vioxx governmentfunde health care program medicaid andor penalty allege consumer fraud act violation february federal district judge anchorage remand alaska lawsuit state court montana attorney general file renew motion remand case federal district court montana state court motion decide shareholder lawsuit previously disclose addition vioxx product liability lawsuit putative class action individual lawsuit federal security law state law file merck current officer director vioxx security lawsuit vioxx security lawsuit coordinate multidistrict litigation district court district new jersey judge stanley chesler consolidated purpose august judge chesler grant deny merck motion dismiss fifth amend class action complaint consolidate security action thing claim base statement voluntary withdrawal vioxx september dismiss october defendant answer fifth amend class action complaint april plaintiff file motion class certification january judge chesler grant motion march plaintiff file motion leave amend complaint add certain allegation expand class period court deny plaintiff motion leave amend complaint expand class period grant plaintiff leave amend complaint add certain allegation exist class period june plaintiff file sixth amend class action complaint july defendant answer sixth amend class action complaint discovery complete closed dispositive motion fully brief previously disclose individual security lawsuit file foreign institutional investor consolidate vioxx security lawsuit october plaintiff file amend complaint pende individual security lawsuit october individual security lawsuit kbc lawsuit prior individual action direct action file district new jersey foreign institutional investor case consolidate vioxx security lawsuit january defendant file motion dismiss individual lawsuit abp lawsuit briefing motion dismiss complete march august judge chesler grant deny motion dismiss abp lawsuit thing certain allege misstatement omission dismiss inactionable state law claim dismiss september defendant answer complaint direct action kbc lawsuit day defendant move dismiss complaint kbc lawsuit statute limitation ground december judge chesler deny motion dismiss kbc lawsuit january defendant answer complaint kbc lawsuit discovery complete direct action close dispositive motion fully brief direct action march february additional individual security complaint file institutional investor opt class action refer new complaint substantially similar complaint direct action consolidate vioxx security lawsuit table content insurance company director officer insurance coverage applicable vioxx security lawsuit remain state upper limit approximately million result previously disclose insurance arbitration additional insurance coverage claim available need upperlevel excess policy provide coverage variety risk dispute insurer availability company insurance coverage claim likely additional dispute amount actually recover policy discuss paragraph state upper limit international lawsuit previously disclose addition lawsuit discuss merck name defendant litigation relate vioxx brazil canada europe israel collectively vioxx international lawsuit previously disclose company enter agreement resolve claim relate vioxx canada pursuant company pay minimum approximately million aggregate maximum approximately million agreement approve court canadas province reserve company believe meritorious defense remain vioxx product liability lawsuit vioxx security lawsuit vioxx international lawsuit collectively vioxx litigation vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect remain vioxx litigation company establish reserve respect canadian settlement certain vioxx product liability lawsuit immaterial settlement relate certain vioxx international lawsuit company immaterial remain reserve relate previously disclose vioxx investigation nonparticipating state litigation continue company establish liability reserve respect vioxx litigation unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation product liability litigation fosamax previously disclose merck defendant product liability lawsuit unite states involve fosamax fosamax litigation december approximately case include approximately plaintiff group file pende merck federal state court include case seek class action certification damage andor medical monitoring approximately action plaintiff allege thing suffer osteonecrosis jaw onj generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax substantially action subject settlement discuss addition plaintiff approximately action generally allege sustained femur fracture andor bone injury femur fracture association use fosamax case allege onj andor jaw relate injury august jpml order certain fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax onj mdl coordinated pretrial proceeding december merck reach agreement principle plaintiff steer committee psc fosamax onj mdl resolve pende onj case appeal fosamax onj mdl state court aggregate million merck psc subsequently formalize term agreement master settlement agreement onj master settlement agreement execute april condition settlement state federal onj plaintiff agree participate settlement plan merck terminate onj master settlement agreement waive participation requirement agree less funding settlement fund july merck elect proceed onj master table content settlement agreement reduce funding level current participation level approximately addition judge oversee fosamax onj mdl grant motion file merck enter order require approximately nonparticipant case remain fosamax onj mdl submit expert report order case proceed onj master settlement agreement effect case allege femur fracture discuss case allege femur fracture march merck submit motion transfer jpml seek federal case allege femur fracture consolidate multidistrict litigation coordinate pretrial proceeding motion transfer grant federal case involve allegation femur fracture transfer multidistrict litigation district new jersey fosamax femur fracture mdl result jpml order approximately case pende fosamax femur fracture mdl december case management order enter require party review case judge joel pisano select case group try initial bellwether case fosamax femur fracture mdl bellwether case glynn merck begin april jury return verdict merck favor april addition june judge pisano grant merck motion judgment matter law glynn case hold plaintiff failure warn claim preempt federal law addition judge pisano enter order august require plaintiff fosamax femur fracture mdl cause case assert claim femur fracture injury take place prior september dismiss base court preemption decision glynn case hearing cause order hold january march judge pisano issue opinion finding claim approximately plaintiff allegedly suffer injury prior september preempt order case dismiss majority plaintiff appeal rule court appeal circuit furthermore june judge pisano grant merck summary judgment gaynor merck case find merck update january fosamax label atypical femur fracture adequate matter law merck adequately communicate change plaintiff gaynor appeal judge pisanos decision circuit august merck file motion request judge pisano enter order require remain plaintiff fosamax femur fracture mdl claim fosamax label inadequate proximate cause allege injury cause case dismiss base court preemption decision rule gaynor case plaintiff oppose motion ask court stay remain case fosamax femur fracture mdl circuit rule appeal judge pisanos preemption decision judge pisano grant merck motion enter request cause order november september judge pisano order party participate mediation process december approximately case allege femur fracture file new jersey state court pending judge jessica mayer middlesex county party select initial group case review fact discovery additional group case review fact discovery select november march respectively december approximately case allege femur fracture file california state court petition file seek coordinate femur fracture case file california state court single judge orange county california petition grant judge thierry colaw currently preside coordinate proceeding march court directed group discovery pool case review fact discovery subsequently schedule galper merck case trial february additional trial schedule july additionally femur fracture case pende state court discovery ongoing fosamax femur fracture mdl state court femur fracture case pende company intend defend lawsuit januviajanumet previously disclose merck defendant product liability lawsuit unite states involve januvia andor janumet december approximately product user claim serve table content pende merck alleging generally use januvia andor janumet cause development pancreatic cancer complaint file different state federal court claim pende consolidated multidistrict litigation proceed district court southern district california call incretinbase therapy product liability litigation proceeding include federal lawsuit allege pancreatic cancer use follow medicine januvia janumet byetta victoza product manufacture pharmaceutical company addition case note company agree december toll statute limitation additional claim company intend defend lawsuit nuvare previously disclose beginning number complaint file jurisdiction assert claim company subsidiarie organon usa inc organon pharmaceuticals usa inc organon international collectively organon company arise organon marketing sale nuvare nuvare litigation combine hormonal contraceptive vaginal ring plaintiff contend organon schering plough thing fail adequately design manufacture nuvare fail adequately warn allege increase risk venous thromboembolism vte pose nuvare andor downplay risk vte plaintiff seek damage injury allegedly sustain product use include alleged death heart attack stroke majority case currently pende federal multidistrict litigation nuvaring mdl venue missouri coordinated proceed new jersey state court pursuant settlement agreement merck negotiate plaintiff counsel effective june merck pay lump total settlement million resolve case file retainer counsel february plaintiffs case join settlement program case dismiss prejudice settlement administration process complete company expect dismissal begin second quarter continue roll basis company certain insurance coverage available currently partially fund company legal fee insurance coverage fund settlement december approximately case outside settlement program remain plaintiff participate settlement chooses proceed case future plaintiff nuvare mdl new jersey state court obligate meet discovery evidentiary requirement case management order nuvare mdl new jersey state court plaintiff fail fully timely satisfy requirement set deadline subject order cause case dismiss prejudice propeciaproscar previously disclose merck defendant product liability lawsuit unite states involve propecia andor proscar december approximately lawsuit involve total approximately plaintiff instance spouse join plaintiff suit allege experience persistent sexual effect follow cessation treatment propecia andor proscar file merck approximately plaintiff allege propecia proscar cause cause prostate cancer male breast cancer lawsuit file federal court state court new jersey federal lawsuit consolidate pretrial purpose federal multidistrict litigation judge john gleeson eastern district new york matter pende state court new jersey consolidated judge jessica mayer middlesex county company intend defend lawsuit governmental proceeding previously disclose june district court eastern district pennsylvania unseal complaint file company federal false claim act employee allege thing company defraud government falsify datum connection clinical study conduct mump component company mmr vaccine complaint allege fraud take place government right participate prosecution lawsuit notify court decline exercise right employee pursue lawsuit involvement government addition putative class action lawsuit table content behalf direct purchaser mmr vaccine charge company misrepresent efficacy mmr vaccine violation federal antitrust law state consumer protection law pende eastern district pennsylvania september court deny merck motion dismiss false claim act suit grant deny motion dismiss thenpende antitrust suit result false claim act suit antitrust suit proceed discovery company intend defend lawsuit previously disclose company receive subpoena office inspector general department health human service behalf attorney office district maryland civil division department justice doj request information relate company marketing singulair dulera inhalation aerosol certain marketing activity january present company cooperate government prior company acquisition cubist cubist acquire optimer pharmaceuticals inc optimer previously disclose cubist prior acquisition optimer optimer aware attempt share grant september optimer thensubsidiary obi pharma inc certain relate matter include potentially improper thousand payment research laboratory july involve individual associate share grant violate certain applicable law include foreign corrupt practice act april optimer selfreporte result preliminary finding securities exchange commission sec doj terminate thenchief financial officer thenvice president clinical development remove chairman board director february independent member optimer board director determine additional remedial action take light prior compliance record keeping conflictofinter issue surround potentially improper payment research laboratory certain relate matter february optimer thenpresident chief executive officer thengeneral counsel chief compliance officer resign request independent member board director company continue cooperate investigation relevant authority review matter optimer take remedial step response internal investigation prior cubist acquisition nonetheless event result lawsuit file optimer certain optimer employee director company require indemnify person cost loss incur connection proceeding company predict ultimate resolution matter optimer person charge violation applicable civil criminal law scope investigation extend new issue company predict potential penalty remedy authority seek collateral consequence government action previously disclose company receive letter doj sec seek information activity number country reference foreign corrupt practice act company cooperate agency request believe inquiry broad review pharmaceutical industry practice foreign country previously disclose company advise doj base information receive closed inquiry matter relate company future company receive additional request information doj sec previously disclose company subsidiary china receive continue receive inquiry operation chinese governmental agency inquiry relate matter involve multinational pharmaceutical company chinese entity business company company policy cooperate authority provide response appropriate commercial litigation awp litigation previously disclose past company andor certain subsidiary name defendant case bring state allege manipulation pharmaceutical manufacturer average wholesale price awp public private payor calculate provider reimbursement level company settle remain awp case subsidiary defendant table content kdur antitrust litigation previously disclose june january scheringplough settle patent litigation upshersmith inc upshersmith esi lederle inc lederle respectively relate generic version kdur scheringploughs longacte potassium chloride product supplement cardiac patient lederle upshersmith file abbreviate new drug application anda follow commencement administrative proceed federal trade commission ftc allege anticompetitive effect settlement resolve schering plough favor putative class nonclass action suit file behalf direct indirect purchaser kdur scheringplough upshersmith lederle consolidated multidistrict litigation district court district new jersey suit claim violation federal state antitrust law state statutory common law cause action seek unspecified damage april indirect purchaser voluntarily dismiss case march district court grant summary judgment defendant remain lawsuit dismiss matter entirety july circuit court appeal reverse district court grant summary judgment remand case proceeding time circuit uphold december decision district court certify certain direct purchaser plaintiff claim class action august company file petition certiorari supreme court seek review circuit decision june supreme court grant petition vacate judgment circuit remand case consideration light recent decision ftc actavis inc decision hold socalled reverse payment payment holder pharmaceutical patent party challenge patent connection settlement dispute violate antitrust law determine basis rule reason analysis september circuit return case district court proceeding accordance actavis standard sale force litigation previously disclose kelli smith file complaint company united states district court district new jersey behalf putative class female sale representative putative subclass female sale representative child claim discriminatory policy practice selection promotion advancement disparate pay differential treatment hostile work environment retaliation federal state discrimination law november company file motion dismiss class claim plaintiff sought grant leave file amend complaint january plaintiff file amend complaint add additional name plaintiff october court deny company motion dismiss strike class claim premature patent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company protect patent right company file patent infringement lawsuit generic company certain product company product market agreement company currently involve patent infringement litigation united states include cancidas cubicin emend injection invanz nasonex nuvare similar lawsuit defend company patent right exist country company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration patent litigation assurance outcome adverse result significantly shorten period exclusivity product respect product acquire merger acquisition potentially significant intangible asset impairment charge cancidas february patent infringement lawsuit file united states xellia pharmaceuticals aps xellia respect xellias application fda seek prepatent expiry approval market generic version cancidas lawsuit automatically stay fda approval xellias application july adverse court decision whichever occur early august patent infringement lawsuit file united states fresenius kabi usa llc fresenius respect freseniuss application fda seek prepatent expiry approval market generic version cancidas lawsuit automatically stay fda approval freseniuss application december adverse court decision whichever occur early table content cubicin march patent infringement lawsuit file united states hospira inc hospira respect hospiras application fda seek prepatent expiry approval market generic version cubicin trial hold february december district court find composition patent expire june valid infringe later patent expire september november find invalid hospira appeal find composition patent invalid company crossappeale find later patent invalid decision uphold appeal hospiras application approve june october patent infringement lawsuit file united states strides inc agila specialties private limit stridesagila respect stridesagilas application fda seek prepatent expiry approval market generic version cubicin lawsuit automatically stay fda approval stridesagilas application february adverse court decision whichever occur early hospira decision uphold appeal stridesagilas application approve june july patent infringement lawsuit file united states fresenius kabi usa llc fresenius respect freseniuss application fda seek prepatent expiry approval market generic version cubicin lawsuit automatically stay fda approval freseniuss application november adverse court decision whichever occur early hospira decision uphold appeal freseniuss application approve june early district court action teva parenteral medicines inc teva pharmaceuticals usa inc teva pharmaceutical industries ltd collectively teva result settlement teva launch december june company obtain pediatric marketing exclusivity cubicin hospira decision uphold appeal teva able launch june october agila specialties inc mylan pharmaceuticals inc file petition inter parte review ipr united states patent trademark office uspto seek invalidity september november patent november fresenius file petition ipr uspto seek invalidity september patent uspto month filing determine institute request ipr proceeding emend injection patent infringement lawsuit file united states sandoz inc sandoz respect sandozs application fda seek prepatent expiry approval market generic version emend injection lawsuit automatically stay fda approval sandozs application july adverse court decision whichever occur early june patent infringement lawsuit file united states accord healthcare inc accord healthcare inc intas pharmaceuticals ltd collectively inta respect intas application fda seek prepatent expiry approval market generic version emend injection company agree inta stay lawsuit pende outcome lawsuit sandoz july patent infringement lawsuit file united states fresenius respect freseniuss application fda seek prepatent expiry approval market generic version emend injection lawsuit automatically stay fda approval freseniuss application november adverse court decision whichever occur early december apotex inc file petition ipr uspto seek invalidity claim compound patent cover emend injection uspto month determine institute request ipr proceeding invanz july patent infringement lawsuit file united states hospira respect hospiras application fda seek prepatent expiry approval market generic version invanz lawsuit automatically stay fda approval hospiras application november adverse court decision whichever occur early july patent infringement lawsuit file united states sandoz respect sandozs application fda seek prepatent approval market generic version invanz hospira sandoz challenge early patent cover invanz party application fda approve patent expire nasonex july patent infringement lawsuit file united states teva pharmaceuticals usa inc teva pharma respect teva pharmas application fda seek prepatent expiry approval market generic version nasonex lawsuit automatically stay fda approval teva pharmas application november adverse court decision whichever occur early decision table content issue june hold merck patent cover mometasone furoate monohydrate valid infringe apotex corps propose product nuvare december company file lawsuit subsidiary actavis plc united states respect company application fda seek prepatent expiry approval sell generic version nuvare antipd antibody patent opposition litigation previously disclose ono pharmaceutical ono european patent broadly claim use antipd antibody company immunotherapy keytruda treatment cancer ono previously license commercial right antipd antibody bristolmyer squibb bms certain market company believe patent invalid file opposition european patent office epo seek revocation june opposition division epo find claim patent valid company receive opposition division write opinion september company submit substantive appeal february april company company oppose european patent own bms ono believe invalid patent valid broadly claim anti antibody include keytruda bms ono recently submit request amend claim patent epo allow amendment claim patent long broadly claim antipd antibodie keytruda company file lawsuit united kingdom seek revocation national version patent july ono bms sue company seek declaration patent infringe marketing keytruda company seek declaration court keytruda infringe patent anticipate issue validity infringement patent hear time court schedule trial begin july bms ono recently notify company request amend claims epo patent intention seek permission court similarly amend national version claim patent long broadly claim antipd antibodie keytruda company file lawsuit seek revocation patent national courts europe time ono bms file patent infringement action company national courts europe time company launch keytruda approve national court determine company infringe valid claim patent ono bms entitle monetary damage include royalty future sale keytruda potentially seek injunction prevent company marketing keytruda country uspto grant patent nos ono ono bms patent equivalent patent respectively september bms ono file lawsuit united states allege marketing keytruda company infringe patent bms ono seek prevent stop market keytruda united states trial matter currently schedule begin november company believe patent patent invalid september company file lawsuit australia seek revocation australian patent equivalent patent ono bms similar patent application company closely monitor pende united states japan countries company confident able market keytruda country approve prevent ono bms patent pende application litigation pende legal proceeding involve company principally product liability intellectual property lawsuit feasible predict outcome proceeding opinion company likelihood loss remote reasonably possible loss associate resolution table content proceeding expect material company financial position result operation cash flow individually aggregate legal defense reserve legal defense cost expect incur connection loss contingency accrue probable reasonably estimable significant factor consider review legal defense reserve follow actual cost incur company development company legal defense strategy structure light scope litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial associate litigation legal defense reserve december december approximately million million respectively represent company good estimate minimum defense cost incur connection outstanding litigation event additional trial event arise course litigation affect ultimate legal defense cost incur company company continue monitor legal defense cost review adequacy associate reserve determine increase reserve time future base factor set forth believe appropriate environmental matter merck facility oss netherland inspect province brabant province pursuant dutch hazard major accident decree site environmental permit province issue penalty allege violation regulation govern prevent manage accident hazardous substance government issue fine allege environmental violation oss facility total thousand company subsequently advise criminal investigation initiate base certain issue form basis administrative enforcement action province company intend defend enforcement action result investigation company subsidiary party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis final cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost site owner operator recalcitrant potentially responsible party management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year table content equity merck certificate incorporation authorize share common stock share prefer stock capital stock summary common stock treasury stock transaction share millions follow common treasury common treasury common treasury stock stock stock stock stock stock balance january purchase treasury stock issuance balance december purchase treasury stock include million share purchase pursuant accelerate share repurchase agreement discuss issuance primarily reflect activity sharebase compensation plan pursuant accelerated share repurchase asr agreement goldman sachs company purchase million share merck common stock billion asr enter pursuant share repurchase program announce noncontrolle interest connection restructure ami merck assume billion par value prefer stock dividend rate annum carry kbi include noncontrolle interest december astrazeneca exercise option acquire merck interest azlp note preferred stock obligation retire sharebase compensation plan company sharebase compensation plan company grant restrict stock unit rsus performance share unit psus certain management level employee company issue rsus employee certain company equity method investee addition employee nonemployee director grant option purchase share company common stock fair market value time grant plan approve company shareholder december million share collectively authorize future grant company sharebase compensation plan award settle primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest fair value stock option rsu award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price rsus certain psus grant december employee participate dividend basis common share dividend nonforfeitable holder rsus psus issue january dividend declare vest period payable employee vest psu performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue rsu psu distribution share company stock end vest performance period generally year subject term applicable award table content total pretax sharebase compensation cost record million million million respectively relate income tax benefit million million million respectively company use blackschole option pricing model determine fair value option grant apply model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect dividend yield riskfree interest rate volatility term option expect dividend yield base historical pattern dividend payment riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option expect life represent time option grant expect outstanding base historical forecast exercise behavior weight average exercise price option grant option respectively weight average fair value option grant option respectively determine follow assumption year end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative stock option plan activity option thousand follows weight weight average average remain aggregate number exercise contractual intrinsic option price term year value outstanding january grant exercise forfeit outstanding december exercisable december additional information pertain stock option plan provide table year end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option table content summary nonveste rsu psu activity share thousand follow rsus psus weight weight average average number grant date number grant date share fair value share fair value nonveste january grant vested forfeited nonveste december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation cost unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary result plan design change approve begin january active participant merck primary define benefit pension plan accrue pension benefit new cash balance formula base age service pay interest transition period january december participant earn great benefit calculate employee legacy final average pay formula new cash balance formula year service december participant earn future benefit cash balance formula addition company provide medical benefit principally eligible retiree dependent postretirement benefit plan company use december yearend measurement date pension plan postretirement benefit plan net periodic benefit cost net periodic benefit cost pension postretirement benefit plan consist follow component pension benefit international postretirement benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement net periodic benefit cost credit decrease net periodic benefit cost pension postretirement benefit plan compare largely attributable change discount rate connection restructuring action note termination charge record pension postretirement benefit plan relate expand eligibility certain employee exit merck connection restructuring activity curtailment record pension postretirement benefit plan table content addition settlement record certain international pension plan obligation fund status summarize information change plan asset benefit obligation fund status amount record december follow pension benefit postretirement international benefit fair value plan asset january actual return plan asset company contribution effect exchange rate change benefit pay settlement fair value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay effect exchange rate change plan amendment curtailment termination benefit settlement benefit obligation december fund status december recognize asset accrue current liability noncurrent liability december accumulate benefit obligation billion billion respectively pension plan billion billion respectively relate pension plan actuarial loss reflect change discount rate plan reflect impact company adoption new retirement plan mortality assumption issue society actuary october table content information relate fund status select pension plan december follow international pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset plan asset entity require use fair value hierarchy maximize use observable input minimize use unobservable input measure fair value level input measure fair value level high priority level low level quote price unadjuste active market identical asset liability level observable input level price quote price similar asset liability input observable corroborate observable market datum substantially term asset liability level unobservable input support little market activity level asset value determine pricing model discount cash flow methodology similar technique significant unobservable input instrument determination fair value require significant judgment estimation december million million respectively approximately respectively company pension investment year end categorize level asset input measure financial asset fall level describe categorization base low level input significant fair value measurement instrument table content fair value companys pension plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation fix income obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security investment derivative liability derivative international pension plan asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation corporate obligation fix income obligation real estate equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacke security investment insurance contract plans level investment real estate fund generally value market appraisal underlie investment fund plan level investment insurance contract generally value credit rate approximate market return invest underlying security market value unobservable determine pricing model discount cash flow methodology similar technique table content table provide summary change fair value include transfer andor financial asset measure fair value significant unobservable input level company pension plan asset insurance real insurance real contract estate total contract estate total pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale balance december international pension plan balance january actual return plan asset relate asset hold december relate asset sell year purchase sale transfer level balance december fair value company postretirement benefit plan asset december asset category follow fair value measurement fair value measurement quote price significant quote price significant active significant active significant market observable unobservable market observable unobservable identical asset input input identical asset input input level level level total level level level total asset cash cash equivalent investment fund develop market equities emerge market equity government agency obligation fix income obligation equity security develop market fix income security government agency obligation corporate obligation mortgage assetbacked security fix income obligation investment derivative table content company establish investment guideline pension postretirement plan create asset allocation expect deliver rate return sufficient meet longterm obligation plan give acceptable level risk target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent longterm nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest international pension plan target investment portfolio varies base duration pension liability local government rule regulation significant percentage plan asset invest equity concentration risk mitigate use strategy diversify management guideline expect contribution expect contribution approximately million pension plan approximately million international pension plan approximately million postretirement benefit plan expect benefit payment expect benefit payment follow international pension postretirement pension benefit benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service amount recognize comprehensive income net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee follow amount reflect component oci pension plan postretirement international benefit plan year end december net loss gain arise period prior service cost credit arise period net loss amortization include benefit cost prior service credit cost amortization include benefit cost estimate net loss gain prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension table content plan million million respectively relate pension plan million million respectively postretirement benefit plan actuarial assumption company reassesse benefit plan assumption regular basis weight average assumption determine pension postretirement benefit plan international pension plan information follow pension postretirement benefit plan international pension plan december net periodic benefit cost discount rate expect rate return plan asset salary growth rate benefit obligation discount rate salary growth rate pension postretirement benefit plan discount rate evaluate measurement date modify reflect prevail market rate portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determine plan basis develop expect rate return plan longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return plan target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return range range pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow december health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect percentage point increase decrease effect total service interest cost component effect benefit obligation saving plan company maintain define contribution saving plan united states company match percentage employee contribution consistent provision plan employee eligible total employer contribution plan million million million respectively table content income expense net income expense net consist year end december interest income interest expense exchange loss net exchange loss reflect million loss venezuelan currency devaluation february venezuelan government devalue currency bolvar fuertes vef dollar vef dollar company recognize loss exchange approximately million result remeasurement local monetary asset liability new rate january venezuela designate hyperinflationary result local foreign operation remeasure dollar impact record result operation net present table include billion gain divestiture mcc gain million relate astrazenecas option exercise million gain divestiture certain ophthalmic product international market gain million relate divestiture sirna partially offset million loss extinguishment debt million goodwill impairment charge relate company joint venture supera note additional information relate transaction net reflect million net charge relate previously disclose settlement enhance litigation interest pay million million million taxis income reconciliation effective tax rate statutory rate follow tax rate tax rate tax rate statutory rate apply income taxis differential arise foreign earning astrazeneca option exercise sale sirna therapeutics inc tax settlement american taxpayer relief act unremitte foreign earning amortization purchase accounting adjustment divestiture merck consumer care restructure health care reform legislation intangible asset impairment charge vioxx enhance litigation settlement state taxis include tax effect contingency reserve research credit tax rate change miscellaneous item table content foreign earning tax rate differential tax rate reconciliation primarily reflect impact operation jurisdiction different tax rate united states particularly ireland switzerland singapore puerto rico operate tax incentive grant earning indefinitely reinveste yield favorable impact effective tax rate compare statutory rate foreign earning tax rate differential include impact intangible asset impairment charge amortization purchase accounting adjustment restructure cost item present separately represent significant separately disclose pretax cost charge substantial portion item relate jurisdiction low tax rate united states impact record expense item low tax rate jurisdiction unfavorable impact effective tax rate compare statutory rate company effective tax rate reflect impact tax increase prevention act sign law december extend research credit control foreign corporation lookthrough provision american taxpayer relief act sign law january extend research credit control foreign corporation lookthrough provision year retroactively january december company record entire benefit million financial statement period include date enactment income taxis consist year end december domestic foreign taxis income consist year end december current provision federal foreign state defer provision federal foreign state table content defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation unremitte foreign earning equity investment pension postretirement benefit compensation relate unrecognized tax benefit net operating loss tax credit carryforward subtotal valuation allowance total defer taxis net deferred income taxis recognize deferred income taxis current asset asset income taxis payable deferred income taxis company net operating loss nol carryforward jurisdiction december million defer taxis nol carryforward relate foreign jurisdiction individually significant valuation allowance million establish foreign nol carryforward foreign defer tax asset addition company approximately million defer tax asset relate tax credit carryforward nol carryforward expect fully utilize prior expiry income taxis pay billion billion billion respectively income taxis pay reflect approximately billion taxis pay divestiture mcc tax benefit relate stock option exercise million million million reconciliation begin end unrecognized tax benefit follow balance january addition relate current year position addition relate prior year position reduction tax position prior year settlement lapse statute limitation balance december amount reflect settlement irs cra discuss company recognize unrecognized tax benefit billion december income tax provision reflect favorable net impact billion company examination numerous tax authority jurisdiction globally company believe reasonably possible total unrecognized tax benefit december decrease billion month result audit closure settlement expiration statute limitation ultimate finalization company examination relevant tax authority include formal administrative legal proceeding significant impact timing table content reversal unrecognized tax benefit company believe reserve uncertain tax position adequate cover exist risk exposure interest penalty associate uncertain tax position amount expense million benefit million million amount reflect beneficial impact tax settlement include discuss liability accrue interest penalty million million december respectively internal revenue service irs currently conduct examination company tax return year conclude issue relate refund claim taxis pay remain examination company federal tax return company currently appeal irs administrative appeal process addition state foreign tax examination progress significant tax jurisdiction state foreign company income tax return open examination period irs finalize examination scheringplough tax year company unrecognize tax benefit year examination exceed adjustment relate examination period company record net million tax provision benefit irs finalize examination scheringplough tax year audit cycle company reach agreement irs adjustment income relate intercompany pricing matter income adjustment reduce nols tax credit carryforward companys reserve uncertain tax position adequate cover adjustment relate examination period additionally previously disclose company seek resolution issue raise examination irs administrative appeal process company record outofperiod net tax benefit million relate issue settle fourth quarter final resolution relate interest owe reach quarter company unrecognized tax benefit relate issue exceed settlement management conclude exclusion benefit material prior year financial statement previously disclose canada revenue agency cra propose adjustment relate intercompany pricing matter issue assessment miscellaneous audit issue tax year merck cra reach settlement year call merck pay additional canadian tax approximately million company unrecognized tax benefit relate matter exceed settlement company record net million tax provision benefit portion taxis pay expect creditable tax purpose company previously establish reserve matter resolution matter material effect company result operation financial position liquidity december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant begin expire table content earning share prior company calculate earning share pursuant twoclass method earning distribute undistributed allocate common share participate security base respective right receive dividend rsus certain psus grant december generally year vest period certain management level employee meet definition participate security rsus psus issue january meet definition participate security begin company long apply twoclass method calculation earning share follow year end december basic earning common share net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding earning common share assume dilution net income attributable merck inc income allocate participate security net income allocate common shareholder average common share outstanding common share issuable average common share outstanding assume dilution issuable primarily sharebased compensation plan million million million respectively common share issuable sharebased compensation plan exclude computation earning common share assume dilution effect antidilutive table content comprehensive income loss change aoci component follow employee cumulative accumulate benefit translation comprehensive derivative investment plan adjustment income loss balance january net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis comprehensive income loss reclassification adjustment pretax tax comprehensive income loss reclassification adjustment net taxis reclassification adjustment pretax tax reclassification adjustment net taxis comprehensive income loss net taxis balance december net taxis relate foreign currency cash flow hedge reclassify aoci sale represent net realize gain loss sale availableforsale investment reclassify aoci income expense net include net amortization prior service cost actuarial gain loss include net periodic benefit cost note include pension plan net loss billion billion december respectively postretirement benefit plan net loss million million december respectively pension plan prior service credit million million december respectively postretirement benefit plan prior service credit million million december table content segment reporting company operation principally manage product basis comprise operate segment pharmaceutical animal health alliance include revenue equity income company relationship azlp june termination date animal health alliance segment material separate reporting include table pharmaceutical segment include human health pharmaceutical vaccine product market directly company joint venture human health pharmaceutical product consist therapeutic preventive agent generally sell prescription treatment human disorder company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization pharmacy benefit manager institution vaccine product consist preventive pediatric adolescent adult vaccine primarily administer physician office company sell human health vaccine primarily physicians wholesaler physician distributor government entity large component pediatric adolescent vaccine sell center disease control prevention vaccine child program fund government additionally company sell vaccine federal government placement vaccine stockpile company animal health operation discover develop manufacture market animal health product include vaccine company sell veterinarians distributor animal producer october company divest consumer care segment note develop manufacture market overthecounter foot care sun care product accounting policy segment describe describe note table content sale company product follow year end december primary care womens health cardiovascular zetia vytorin diabete januvia janumet general medicine women health nuvare implanonnexplanon dulera follistim hospital specialty hepatitis pegintron victrelis hiv isentress acute care cancidas invanz noxafil bridion primaxin immunology remicade simponi cosopttrusopt oncology emend temodar keytruda diversify brand respiratory nasonex singulair clarinex cozaarhyzaar arcoxia fosamax propecia zocor remeron vaccines gardasil proquadmmr iivarivax zostavax pneumovax rotateq pharmaceutical total pharmaceutical segment sale segment sale total segment sale amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate amount reflect supply sale sanofi pasteur msd pharmaceutical primarily reflect sale human health pharmaceutical product include product franchise list separately represent nonreportable segment animal health alliance consumer care divestiture october note alliance segment include revenue company relationship azlp termination june note revenue primarily comprise miscellaneous corporate revenue include revenue hedging activity sale relate divested product business supply sale include segment result revenue include million receive merck connection sale marketing right saphris note revenue reflect million revenue outlicense pipeline compound revenue include thirdparty manufacture sale substantial portion divest october note table content consolidated revenues geographic area derive follow year end december united states europe middle east africa asia pacific japan latin america reconciliation total segment profit consolidate income taxis follow year end december segment profit pharmaceutical segment segment total segment profit profit unallocate interest income interest expense equity income affiliate depreciation amortization research development amortization purchase accounting adjustment restructure cost gain divestiture merck consumer care gain astrazeneca option exercise gain divestiture certain ophthalmic product loss extinguishment debt net charge relate settlement enhance litigation unallocate net segment profit comprise segment sale standard cost certain operating expense directly incur segment internal management reporting present chief operating decision maker merck allocate material production cost standard cost majority research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit addition cost related restructuring activity amortization purchase accounting adjustment allocate segment profit loss primarily comprise miscellaneous corporate profit loss operate profit loss relate thirdparty manufacture sale divest product business supply sale unallocated net include expense corporate manufacturing cost center goodwill product intangible asset impairment charge gain loss sale business miscellaneous income expense item table content equity income affiliate depreciation amortization include segment profit follow pharmaceutical total year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization year end december include segment profit equity income affiliate depreciation amortization property plant equipment net geographic area locate follow year end december united states europe middle east africa asia pacific latin america japan company disaggregate asset product service basis internal management report information present table content report independent register public accounting firm board director shareholders merck inc opinion accompany consolidated balance sheet relate consolidated statement income comprehensive income equity cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso company management responsible financial statement maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include management report item responsibility express opinion financial statement company internal control financial reporting base integrated audits conduct audits accordance standard public company accounting oversight board united states standard require plan perform audits obtain reasonable assurance financial statement free material misstatement effective internal control financial reporting maintain material respect audits financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation audit internal control financial reporting include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk audits include perform procedure consider necessary circumstance believe audits provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate pricewaterhousecooper llp florham park new jersey february table content supplementary datum select quarterly financial datum contain condense interim financial datum table condense interim financial datum unaudite million share amount sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder sale material production marketing administrative research development restructuring cost equity income affiliate income expense net income taxis net income attributable merck inc basic earning common share attributable merck inc common shareholder earning common share assume dilution attributable merck inc common shareholder amount reflect divestiture merck consumer care business october note include billion gain sale amount include loss extinguishment debt note amount include gain sale business note additional year expense health care reform fee amount include net benefit relate settlement certain federal income tax issue note amount include gain astrazenecas option exercise note amount include tax benefit relate sale sirna therapeutics inc note amount reflect acquisition divestiturerelated cost note impact restructuring action note table content item change disagreement accountant account financial disclosure applicable item control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december pricewaterhousecooper llp independent register public accounting firm perform assessment effectiveness company internal control financial reporting attestation report include filing management report management responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice annually employee company require complete code conduct training include financial stewardship training reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule securities exchange act company internal control financial reporting design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle united states america management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission base evaluation management conclude internal control financial reporting effective december table content inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate effectiveness company internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm state report appear kenneth frazier robert davis chairman president executive vice president chief executive officer chief financial officer item information table content iii item director executive officer corporate governance require information director nominee incorporate reference discussion proposal election director company proxy statement annual meeting shareholder hold information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting shareholder hold company code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer controller code conduct available company website wwwmerckcomaboutcodeofconductpdf merck employee responsible adhering business practice accordance law ethical principle reflect high standard corporate individual behavior print copy send charge shareholder request write chief ethic compliance officer merck inc galloping hill road kenilworth require information identification audit committee audit committee financial expert incorporate reference discussion head board meeting committee companys proxy statement annual meeting shareholder hold item executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity award table option exercise stock vest table pension benefit table nonqualifie defer compensation table potential payment termination change control include discussion subheading separation change control footnote information table company proxy statement annual meeting shareholder hold require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting shareholder hold require information heading compensation committee interlock insider participation compensation benefit committee report incorporate reference company proxy statement annual meeting shareholder hold table content item security ownership certain beneficial owner management relate stockholder matter information respect security ownership certain beneficial owner management incorporate reference discussion head stock ownership information company proxy statement annual meeting shareholder hold equity compensation plan information follow table summarize information option warrant right equity compensation company equity compensation plan close business december table include information tax qualify plan merck saving plan number number security remain security available future issue weightedaverage issuance equity exercise exercise price compensation plan outstanding outstanding exclude option warrant option warrant security right right reflect column plan category equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow shareholderapprove plan merck sharp dohme incentive stock plan merck inc nonemployee directors stock option plan merck inc scheringplough stock incentive plan exclude approximately share restrict stock unit performance share unit assume maximum payout merck sharp dohme incentive stock plan exclude share phantom stock defer msd employee deferral program share phantom stock defer msd director deferral program item certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head related person transaction company proxy statement annual meeting shareholder hold require information director independence incorporate reference discussion head independence director company proxy statement annual meeting shareholder hold item principal accountant fee service information require item incorporate reference discussion audit committee beginning caption pre approval policy service independent register public accounting firm fee service provide independent register public accounting firm company proxy statement annual meeting shareholder hold table content item